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A B S T R A C T
Background
Malaria caused by Plasmodium vivax requires treatment of the blood-stage infection and treatment of the hypnozoites that develop in the
liver. This is a challenge to effective case management of P vivax malaria, as well as being a more general substantial impediment to malaria
control. The World Health Organization (WHO) recommends a 14-day drug course with primaquine, an 8-aminoquinoline, at 0.25 mg/kg/
day in most of the world (standard course), or 0.5 mg/kg/day in East Asia and Oceania (high-standard course). This long treatment course
can be difficult to complete, and primaquine can cause dangerous haemolysis in individuals with glucose-6-phosphate dehydrogenase
(G6PD) deficiency, meaning that physicians may be reluctant to prescribe in areas where G6PD testing is not available. This Cochrane
Review evaluated whether more patient-friendly alternative regimens are as efficacious as the standard regimen for radical cure ofP vivax
malaria.
Objectives
To assess the efficacy and safety of alternative primaquine regimens for radical cure of P vivax malaria compared to the standard or high-
standard 14 days of primaquine (0.25 or 0.5 mg/kg/day), as well as comparison of these two WHO-recommended regimens.
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL); MEDLINE (PubMed); Embase (Ovid); and LILACS (BIREME) up to 17 December 2018. We also searched the WHO International Clinical
Trials Registry Platform (ICTRP) and ClinicalTrials.gov, and checked the reference lists of all studies identified by the above methods.
Selection criteria
Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-
based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose,
or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0.25 or 0.5 mg/kg/day for 14
days), or a comparison of these two WHO-recommended regimens.
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Data collection and analysis
Two review authors independently assessed trial eligibility and quality, and extracted data. We calculated risk ratios (RRs) with 95% con-
fidence intervals (CIs) for dichotomous data. We grouped efficacy data according to length of follow-up. We analysed safety data where
this information was included.
Main results
High-standard 14-day course versus standard 14-day course
Two RCTs compared the high-standard 14-day regimen with the standard 14-day regimen. People with G6PD deficiency and pregnant
or lactating women were excluded. We do not know if there is any difference in P vivax recurrences at 6 months with 0.5 mg/kg/day pri-
maquine therapy for 14 days compared to 0.25 mg/kg/day primaquine therapy for 14 days (with chloroquine: RR 0.82, 95% CI 0.47 to 1.43,
639 participants, very low-certainty evidence; with chloroquine or an ACT: RR 1.11, 95% CI 0.17 to 7.09, 38 participants, very low-certain-
ty evidence). No serious adverse events were reported. We do not know whether there is a difference in adverse events with the higher
dosage (very low-certainty evidence).
0.5 mg/kg/day primaquine for 7 days versus standard 14-day course
Five RCTs compared 0.5 mg/kg/day primaquine for 7 days with the standard 14-day course. There may be little or no difference in P vivax
recurrences at 6 to 7 months when using the same total dose (0.5 mg/kg/day to 210 mg) over 7 days as compared to 14 days (RR 0.96, 95%
CI 0.66 to 1.39; 1211 participants; low-certainty evidence). No serious adverse events were reported. There may be little or no difference
in the number of adverse events known to occur with primaquine between the primaquine shorter regimen as compared to the longer
regimen (RR 1.06, 95% CI 0.64 to 1.76; 1154 participants; low-certainty evidence). We do not know whether there is any difference in the
frequency of anaemia or discontinuation of treatment between groups (very low-certainty evidence). Three trials excluded people with
G6PD deficiency, and two did not provide this information. Pregnant and lactating women were either excluded or no details were provided
regarding their inclusion or exclusion.
0.75 mg/kg primaquine/week for 8 weeks versus high-standard course
One RCT compared weekly primaquine with the high-standard 14-day course. G6PD-deficient patients were not randomized but were
included in the weekly primaquine group. Only one G6PD-deficient participant was detected during the trial. We do not know whether
weekly primaquine increases or decreases recurrences of P vivax compared to the 14-day regimen at 11 months' follow-up (RR 3.18, 95%
CI 0.37 to 27.6; 122 participants; very low-certainty evidence). No serious adverse events and no episodes of anaemia were reported.
Three other RCTs evaluated different alternative regimens and doses of primaquine, but one of these RCTs did not have results available,
and two used regimens that have not been widely used and the evidence was of very low certainty.
Authors' conclusions
Although limited data were available, the analysis did not detect a difference in recurrence between the 7-day regimen and the standard
14-day regimen of 0.5 mg/kg/day primaquine, and no serious adverse events were reported in G6PD-normal participants taking 0.5 mg/
kg/day of primaquine. This shorter regimen may be useful in G6PD-normal patients if there are treatment adherence concerns. Further
large high-quality RCTs are needed, such as the IMPROV trial, with more standardised comparison regimens and longer follow-up to help
resolve uncertainties.
16 September 2019
Update pending
Authors currently updating
The update is due to be published in December 2019.
P L A I N   L A N G U A G E   S U M M A R Y
Primaquine to cure people with Plasmodium vivax malaria: comparing dosing schedules
Plasmodium vivax malaria can sometimes cause potentially life-threatening illness, and the infection continues to make many people
unwell. The infection includes a liver stage, and this requires primaquine to eradicate it and prevent the infection recrudescing. However,
the current dosing schedule requires 14 days of daily treatment.
What are the concerns about primaquine?
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
2
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Primaquine is the only drug currently recommended to treat the liver parasites in P vivax malaria. It can cause anaemia in people with
glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is a relatively common genetic blood disorder. Shorter regimens would
help reduce the risk of default with the current two-week regimen.
What does the research say?
We summarized trials that compared the World Health Organization (WHO)-recommended primaquine regimen of 15 to 30 mg per day
for 14 days with the same or higher doses of primaquine given over different lengths of time to determine whether alternative regimens
were as successful as the recommended courses at preventing future episodes of P vivax malaria. We searched for trials up to 17 December
2018, and included nine randomized controlled trials (studies in which participants are assigned to one of two or more treatment groups
in a random manner) in our analysis.
When using 30 mg per day compared to 15 mg per day primaquine therapy for 14 days, we do not know if there is any difference in P vivax
recurrences at 6 months (very low-certainty evidence). No serious side effects were reported, but it is unclear whether or not there is a
difference in other side effects between doses (very low-certainty evidence).
When using 30 mg primaquine per day for 7 days compared to 15 mg per day for 14 days, there may be no difference in P vivax recurrences
at 6 to 7 months (low-certainty evidence). No serious adverse events were reported. There may be no difference in the number of side
effects known to occur with primaquine between the two treatment regimens (low-certainty evidence).
We do not know whether weekly primaquine increases or decreases recurrences of P vivax compared to the 14-day regimen at 11 months'
follow-up (very low-certainty evidence).
Further large high-quality RCTs are needed, such as the IMPROV trial, to help improve the certainty of the evidence around alternative
regimens.
How up-to-date is this review?
The review authors searched for studies up to 17 December 2018.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   ‘Summary of findings' (main comparison)
0.5 mg/kg/day for 7 days versus standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: India, Peru, Brazil
Intervention: 0.5 mg/kg/day primaquine for 7 days (adult dose 30 mg)
Comparison: standard 14-day course of primaquine (0.25 mg/kg/day, adult dose 15 mg)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
standard 14-
day course
primaquine
Risk with
0.5mg/kg/
day pri-
maquine for
7 days
Relative ef-
fect
(95% CI)
№ of partici-
pants
(trials)
Certainty of the evidence
(GRADE)
Comments
Recurrence of P vivax
parasitaemia
Follow-up: range 6
months to 7 months
89 per 1000 86 per 1000
(59 to 124)
RR 0.96
(0.66 to 1.39)
1211
(4 RCTs)
⊕⊕⊝⊝
LOWa,b
Due to risk of bias and impre-
cision
There may be little or no difference be-
tween 0.5 mg/kg/day primaquine for 7
days and the standard 14-day course.
Serious adverse effects See comment See comment — 1427
(5 RCTs)
— No events reported.
Adverse events that re-
sult in the discontinua-
tion of treatment
3 per 1000 3 per 1000
(0 to 20)
RR 1.04
(0.15 to 7.38)
1154
(4 RCTs)
⊕⊝⊝⊝
VERY LOWc,d
due to risk of bias and impre-
cision
We do not know if there is any difference
in adverse events that result in treatment
discontinuation between 0.5 mg/kg/day
primaquine for 7 days and the standard
14-day course.
Adverse effects known
to occur with pri-
maquine
44 per 1000 47 per 1000
(28 to 78)
RR 1.06
(0.64 to 1.76)
1154
(4 RCTs)
⊕⊕⊝⊝
LOWc,e
Due to risk of bias and impre-
cision
There may be little or no difference in the
frequency of adverse events known to oc-
cur with primaquine between 0.5 mg/kg/
day primaquine for 7 days and the stan-
dard 14-day course.
Anaemia or change in
haemoglobin status
0 per 1000 0 per 1000
(0 to 0)
RR 3.0 (0.51 to
174.01)
240
(1 RCT)
⊕⊝⊝⊝
VERY LOWf,g,h
We do not know if the occurrence of
anaemia differs between the 2 treatment
regimens.
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Due to risk of bias, indirect-
ness, and imprecision
Adverse events known
to occur with chloro-
quine
0 per 1000 0 per 1000
(0 to 0)
RR 9.40
(0.51 to
174.01)
779
(1 RCT)
⊕⊝⊝⊝
VERY LOWi,j,k
Due to risk of bias, indirect-
ness, and imprecision
We do not know if there is a difference
in the number of participants experi-
encing adverse events known to occur
with chlorquine between the 2 treatment
groups.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once for risk of bias: Rajgor 2014 IND, which contributed the most weight to the meta-analysis, was at high risk of selection bias due to no allocation concealment
and high risk of attrition bias. Although Pareek 2015 IND was at risk of selection bias as well as other bias for being funded and carried out by drug company, it only contributed
a small amount of weight to the meta-analysis.
bDowngraded once for imprecision: wide CIs - may be 34% reduction in malaria recurrences or 40% increase with 0.5 mg/kg/day primaquine for 7 days.
cDowngraded once for risk of bias: Rajgor 2014 IND was at high risk of selection bias due to no allocation concealment and high risk of attrition bias. Pareek 2015 IND was at risk
of selection bias as well as other bias for being funded and carried out by drug company.
dDowngraded twice for serious imprecision: very few events (only four events occurring in one trial, Rajgor 2014 IND), very wide CIs.
eDowngraded once due to imprecision: wide CIs.
fDowngraded once due to risk of bias: Pareek 2015 IND was at risk of selection bias and other bias (funded and performed by drug company).
gDowngraded once for indirectness: only one study conducted in G6PD-normal adults in India (Pareek 2015 IND).
hDowngraded twice for serious imprecision: only one event, very wide CIs.
iDowngraded once for risk of bias: Rajgor 2014 IND at risk of bias selection bias due to no allocation concealment and attrition bias.
jDowngraded once for indirectness: only one study conducted in G6PD-normal adults in India (Rajgor 2014 IND).
kDowngraded twice for serious imprecision: few events, very wide CIs.
 
 
Summary of findings 2.   ‘Summary of findings' table 2
High-standard 14-day regimen versus standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: India
Intervention: high-standard 14-day course of primaquine (0.5 mg/kg/day, adult dose 30 mg)
Comparison: standard 14-day course of primaquine (0.25 mg/kg/day, adult dose 15 mg)
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Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
standard 14-
day course
primaquine
Risk with
high-stan-
dard 14-day
course pri-
maquine
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of the evidence
(GRADE)
Comments
Recurrence of P vivax par-
asitaemia
follow-up: range 6 months
to 7 months
Blood-stage treatment:
chloroquine
81 per 1000 66 per 1000
(34 to 116)
RR 0.82
(0.47 to 1.43)
639
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,c
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in P vivax recurrences between
high-standard or standard 14-day
courses of primaquine given with
chloroquine.
Recurrence of P vivax par-
asitaemia
follow-up: range 6 months
Blood-stage treatment:
chloroquine or an ACT
100 per 1000 111 per 1000
(17 to 709)
RR 1.11 (0.17
to 7.09)
38
(1 RCT)
⊕⊝⊝⊝
VERY LOWd,e,f
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in P vivax recurrences between
high-standard or standard 14-day
courses of primaquine given with
chloroquine or an ACT.
Serious adverse effects 0 per 1000 0 per 1000
(0 to 0)
Not estimable 816
(2 RCTs)
— No events reported.
Adverse events that result
in the discontinuation of
treatment
5 per 1000 21 per 1000
(5 to 98)
RR 4.19
(0.90 to 19.60)
778
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,d,g
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in adverse events resulting in
treatment discontinuation between
high-standard or standard 14-day
courses of primaquine.
Adverse effects known to
occur with primaquine
13 per 1000 34 per 1000
(12 to 95)
RR 2.72
(0.98 to 7.57)
778
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,h
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in adverse events known to oc-
cur with primaquine between high-
standard or standard 14-day courses
of primaquine.
Adverse events known to
occur with chloroquine
0 per 1000 0 per 1000
(0 to 0)
RR 9.43
(0.51 to
174.47)
778
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,h
due to indirectness, risk of bias,
and imprecision
We do not know if there is any dif-
ference in adverse events associat-
ed with chloroquine between the 2
treatment groups.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
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Abbreviations: ACT: artemisinin-based combination therapy; CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once for indirectness: only one trial conducted in India in G6PD-normal adults (Rajgor 2014 IND).
bDowngraded once for risk of bias: open-label - no allocation concealment, risk of selection bias; risk of attrition bias - high percentage not completing six months' follow-up
with minimal explanation.
cDowngraded once for imprecision: wide CIs - range of 58% reduction in malaria recurrences at 6 months with high-standard 14-day course of primaquine to 43% increase in
number of malaria recurrences.
dDowngraded once for indirectness: only one trial conducted in India in G6PD-normal adults (Saravu 2018 IND).
eDowngraded once for risk of bias: no blinding, high rate of loss to follow-up.
fDowngraded once for imprecision: wide CIs - range of 83% reduction in malaria recurrence to 609% increase in malaria recurrences with the high-standard 14-day regimen.
gDowngraded once for imprecision: wide CIs 0.9 to 19.6 - range of 10% reduction in adverse events with high-standard 14-day course to 186% increase in adverse events.
hDowngraded once for imprecision: wide CIs.
 
 
Summary of findings 3.   ‘Summary of findings' table 3
0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: Pakistan
Intervention: 0.75 mg/kg primaquine/week for 8 weeks (adult dose 45 mg)
Comparison: high-standard 14-day course primaquine (0.5 mg/kg/day, adult dose 30 mg)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
high-stan-
dard 14-day
course pri-
maquine
Risk with once-
weekly 0.75
mg/kg pri-
maquine for 8
weeks
Relative effect
(95% CI)
№ of partici-
pants
(trials)
Certainty of the evidence
(GRADE)
Comments
Recurrence of P vivax
malaria
Follow-up: 8 months
0 per 1000 0 per 1000
(0 to 0)
RR 7.00
(0.38 to 127.32)
126
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,c
due to risk of bias, indirectness,
and imprecision
We do not know if weekly pri-
maquine reduces the risk of
malaria recurrences when com-
pared to the high-standard 14-
day course.
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Recurrence of P vivax
malaria
Follow-up: 11
months
19 per 1000 59 per 1000
(7 to 511)
RR 3.18
(0.37 to 27.60)
122
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,d
due to risk of bias, indirectness,
and imprecision
We do not know if weekly pri-
maquine reduces the risk of
malaria recurrences when com-
pared to the high-standard 14-
day course.
Serious adverse ef-
fects
0 per 1000 0 per 1000
(0 to 0)
Not estimable 129
(1 RCT)
— No events reported.
Anaemia (haemoglo-
bin < 7 g/dL)
0 per 1000 0 per 1000
(0 to 0)
Not estimable 129
(1 RCT)
— No events reported.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by 1 for risk of bias: Leslie 2008 PAK was at high risk of bias for randomization process, allocation concealment, and incomplete outcome data.
bDowngraded by 1 for indirectness: only one study conducted in Pakistan, only one G6PD-deficient adult included in one trial (in weekly arm).
cDowngraded by 2 for serious imprecision: few events, very wide CIs.
dDowngraded by 2 for serious imprecision: few events, very wide CIs.
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B A C K G R O U N D
Malaria is a potentially life-threatening disease caused by the Plas-
modium parasite, which is transmitted by the bite of an infected
female Anopheles mosquito. Five species of Plasmodium malaria
parasites can cause malaria disease in humans, of which Plasmodi-
um vivax and Plasmodium falciparum are the most important (WHO
2016). In 2017, an estimated 219 million cases of malaria occurred
worldwide and an estimated 435,000 people died from the disease
(WHO 2018). The World Health Organization (WHO) aims to reduce
malaria case load and mortality by at least 90% by 2030 (WHO
2016).
Historically, P vivax infection was thought to be a milder form of
malaria, and researchers have focused on P falciparum due to the
high number of deaths it causes (Bassat 2016). In recent years, it's
been shown that the morbidity and mortality of P vivax have been
underestimated, with evidence of direct fatality and contribution
to mortality in patients who have other comorbidities, such as mal-
nutrition, HIV, or coexisting infections (Baird 2013; Bhattacharjee
2013; Rizvi 2013; Singh 2013; Battle 2014; Douglas 2014; Kochar
2014; Arévalo-Herrera 2015; Baird 2015b). Repeated P vivax infec-
tions through childhood and adulthood also affect personal well-
being, development, and education and can thus negatively impact
economic development, both for the individual and the communi-
ty (Mendis 2001). P vivax malaria in pregnancy is associated with
maternal anaemia, spontaneous abortion, stillbirth, and low birth-
weight, with especially poor pregnancy outcomes for women with
severe infection (McGready 2012; Rijken 2012; Brutus 2013).
Description of the condition
P vivax infection caused an estimated 7.5 million cases of malaria
in 2017 (WHO 2018). The geographical distribution ofP vivax malar-
ia is more widespread than any of the other forms of human malar-
ia, with around 35% of the world’s population thought to be at risk
(Howes 2016) ). Co-infection with P falciparum is also common in
many regions (Kumar 2007; Mueller 2009). As malaria control ac-
celerates, the P vivax proportion in co-endemic areas tends to rise
compared to that of P falciparum, which highlights the importance
and challenge of this infection (John 2012).
P vivax is important because as many countries progress towards
malaria elimination, the parasite becomes a roadblock to eradica-
tion (Cibulskis 2015; Bassat 2016). Despite a reported 45% reduc-
tion in P vivax malaria cases between 2010 and 2016 (WHO 2017),
the parasite has several characteristics that enable it to evade con-
trol (Newby 2016). The early appearance of gametocytes in the
blood, often prior to symptoms of malaria, increases the chance
of onward transmission by mosquitoes (Mendis 2001). P vivax dif-
fers from P falciparum in that as well as having a blood-stage in-
fection, hypnozoites develop in the liver that can be dormant for
weeks to months before developing into an infection (White 2011).
What triggers these relapses is not well-understood. There is diffi-
culty in distinguishing between relapse (hypnozoite activation), re-
crudescence (subpar treatment of the initial blood-stage infection),
and re-infection (new infection with P vivax) (Imwong 2007). A study
in Papua New Guinea suggested that relapses cause four-fiThs of P
vivax infections (Robinson 2015), reinforcing the importance of re-
lapse in sustaining transmission (White 2011). Parasites show high
genetic diversity, even in countries that are at malaria elimination
stage (Koepfli 2015). P vivax is likely underestimated worldwide, as
the dormant liver stage is not detected in routine surveys (Geth-
ing 2012). Submicroscopic infections and asymptomatic infection
reservoirs may also lead to underdiagnosis or misdiagnosis. A sys-
tematic review showed that across all study sites, the polymerase
chain reaction (PCR) prevalence of P vivax was significantly higher
than that identified by light microscopy (Cheng 2015). The effect
this may have on P vivax malaria studies is unclear.
There are different strains of P vivax according to geographical re-
gion/endemicity areas, with relapse patterns that vary by latency
(time to first relapse), likelihood of relapse, and frequency of relaps-
es, which further complicates the assessment of efficacy of drugs
on relapses (Battle 2014; White 2016). Strains commonly found in
Southeast Asia and Oceania (including the ‘Chesson’ strain isolated
from an individual infected in Papua New Guinea) have the shortest
latency time to relapse, starting as early as three weeks after first
infection (if untreated with a hypnozoiticidal drug) (Ehrman 1945).
These areas correspond to zones 10 and 12 in Battle 2014. Indian
and Pakistan strains (zone 8) exhibit heterogeneity in relapse laten-
cy, incidence, and frequency, while South American strains (zone 3)
have a pattern of short latency to first relapse and less frequent re-
lapses than in zones 10 and 12 (Battle 2014). The temperate strains
(which include those from Korea in zone 11) relapse much more
slowly (John 2012; Battle 2014). Strains of the type in zones 10 and
12, referred to here as 'East Asia and Oceania', are recommended
to receive higher doses of primaquine (the high-standard course of
0.5 mg/kg/day rather than standard 0.25 mg/kg/day for 14 days) to
prevent relapses (WHO 2015), apparently based on research done
in the 1950s and 1960s (Coatney 1953; Jones 1953; Vivona 1961;
Maffi 1971; Clyde 1977), although not all these studies were done
with strains from the targeted geographic area.
Primaquine, an 8-aminoquinoline, has until very recently been the
only drug available on the market for treating the hypnozoite stage
of infection (Ashley 2014). One of the main barriers in P vivax treat-
ment is the reluctance to use primaquine due to it potentially caus-
ing haemolysis in patients with glucose-6-phosphate dehydroge-
nase (G6PD) deficiency. G6PD deficiency is the most common en-
zyme deficiency worldwide and affects red blood cells by leading to
their premature lysis (Nkhoma 2009). G6PD deficiency is common
in countries where P vivax malaria is endemic, with an estimated
population prevalence of 8% (Howes 2012). Within G6PD deficien-
cy, there are differing phenotypes, meaning some people may be
mildly sensitive to primaquine, while others may be very sensitive
and experience life-threatening haemolysis (Baird 2015a), which
explains the varying responses to primaquine. In many areas where
P vivax is predominant, testing for G6PD deficiency is not available
locally (Baird 2015b). In 2018 the US Food and Drug Administra-
tion (FDA) approved a newer alternative, another 8-aminoquinoline
known as tafenoquine (MMV 2018), which has shown promise in re-
ducing relapses, but there are increased safety concerns in patients
with undiagnosed G6PD deficiency compared to primaquine, due
to its longer half-life (Rajapakse 2015).
Description of the intervention
People with P vivax malaria require treatment with an antimalari-
al drug to treat the blood-stage infection, and a drug to treat the
hypnozoite stage (radical cure). The WHO recommends treatment
with either chloroquine or an artemisinin-based combination ther-
apy (ACT) for the blood-stage infection, with 0.25 to 0.5 mg/kg/day
primaquine for 14 days for the liver stages (WHO 2015). Artemisinin-
based combination therapies and chloroquine have been shown to
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be effective and comparable in treating the blood-stage infection
of P vivax malaria (Gogtay 2013).
A previous Cochrane Review showed that primaquine regimens of
five days or fewer had similar recurrence rates to placebo or no pri-
maquine. Of the comparisons included in the review, a regimen of
0.25 mg/kg/day (15 mg) a day of primaquine for 14 days had the
lowest recurrence rates of P vivax infection (Galappaththy 2013).
There were no trials at that time that compared higher doses of pri-
maquine at 14 or 7 days.
Primaquine was first made available to North American soldiers
in the 1950s (Baird 2004). Its mechanism and metabolism are not
widely understood, but it has a broad spectrum of activity against
the Plasmodium parasite. As well as preventing relapse of P vivax
malaria by targeting the latent and developing hypnozoites in the
liver, it is also used in malaria prophylaxis (Baird 2003). It is ab-
sorbed from the gastrointestinal tract, has a half-life of about four
to nine hours, and crosses the placenta in pregnancy (Baird 2004).
New advancements in studying P vivax in humanized mice may lead
to a greater understanding of the mechanism of action of the drug
(Mikolajczak 2015).
Adverse effects of primaquine include production of methaemo-
globin, an oxidated state of haemoglobin that cannot transport
oxygen to tissues. Methaemoglobinaemia (an abnormal buildup of
methaemoglobin) can result in cyanosis when levels exceed 10% of
the usual haemoglobin level (Vale 2009). As described above, pri-
maquine causes haemolysis in people with G6PD deficiency, which
leads to anaemia (Ashley 2014). When taken on an empty stom-
ach it can cause abdominal pain and gastrointestinal upset (Vale
2009). Safe use of primaquine during pregnancy has not been es-
tablished. The radical cure with primaquine can be delayed until af-
ter pregnancy. With regard to breastfeeding patients, a recent study
showed that the levels of primaquine in breast milk may not be suf-
ficient to cause haemolysis even in a G6PD-deficient baby (Gilder
2018), but it is not recommended at this time.
How the intervention might work
The WHO advises that 0.25 mg to 0.5 mg/kg/day of primaquine for
14 days should be used for radical cure of P vivax malaria in patients
over six months old, excluding people with G6PD deficiency and
those who are pregnant or breastfeeding (WHO 2015).
There has been suggestion of failure of the regimen of 0.25 mg/kg/
day for 14 days (hereafter referred to as the 'standard 14-day reg-
imen') of primaquine for the Chesson strain of P vivax, which was
behind the suggestion of the increased dosing of 0.5 mg/kg/day in
East Asia and Oceania (hereafter referred to as the 'high-standard
14-day regimen'). However, evidence for the choice of the high-
standard regimen is not presented in the WHO treatment guide-
lines (WHO 2015). The previous Cochrane Review, Galappaththy
2013, found no trials that compared the high-standard 14-day reg-
imen to the standard 14-day regimen. The WHO recommends a
weekly dose of 0.75 mg/kg for eight weeks for patients with G6PD
deficiency, but the evidence for this is of low quality, as there are
few high-quality trials (WHO 2015).
The 14-day course of primaquine can lead to treatment adherence
issues, as well as to safety concerns about haemolysis in places
where G6PD testing is not available, meaning that shorter courses
of primaquine are desirable. Failure to treat the hypnozoite stage of
P vivax malaria leads to repeated relapses, morbidity, and persis-
tent infection. The logic framework for developing efficacious and
safe treatment regimens for P vivax is illustrated in Figure 1.
 
Figure 1.   Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite activation.
 
It has long been suggested that it may be the total dose of pri-
maquine that is important in the treatment of the hypnozoite stage
rather than the length of the course (Schmidt 1977). If a higher dose
of primaquine could be administered safely over a shorter peri-
od of time, it may improve adherence rates, thus reducing relapse
rates and morbidity and mortality resulting from P vivax infection.
There are small trials from the 1970s that suggest that shorter, high-
er-dose regimens were as efficacious as the 14-day courses (Clyde
1977; Saint-Yves 1977). At the time of the previous Cochrane Review
(Galappaththy 2013), there were no recent large high-quality trials
that had investigated the use of higher doses given over seven days.
We planned to include any such trials in this Cochrane Review.
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Why it is important to do this review
The use of primaquine for radical cure of P vivax malaria contin-
ues to pose a therapeutic dilemma for healthcare providers in ar-
eas without adequate screening for G6PD status. Clinicians must ei-
ther choose to give primaquine and risk haemolysis if the patient
is G6PD-deficient, or withhold treatment and accept the complica-
tions of ongoing parasite infection and relapses. This is why when
clinicians choose to treat with primaquine they prefer a lower dose
over a more prolonged period, which then risks difficulties with ad-
herence and thus reduced effectiveness.
We know from the previous Cochrane Review on primaquine with
chloroquine for radical cure that the standard 14-day regimen of
0.25 mg/kg/day (15 mg per day or 210 mg total dose) is better
than shorter regimens of similar daily doses and placebo (Galap-
paththy 2013). In fact, the regimen of 0.25 mg/kg/day for 5 days of
primaquine did not reduce recurrences compared to treating with
chloroquine alone.
A major problem with the radical cure of P vivax is difficulty with
the adherence of the 14-day course of primaquine, which has led to
many countries shortening the regimen. Peru was one such exam-
ple, although a study revealed that patients often still discontinued
the therapy after around three days, when they started to feel bet-
ter (Grietens 2010). A study that compared directly observed ther-
apy (DOT) for 14 days of primaquine versus non-DOT primaquine
found that the P vivax recurrence rate was significantly lower in the
DOT group (Takeuchi 2010). These problems have led to a more ur-
gent call for shorter treatment regimens. Various trials are inves-
tigating regimens that revise dosing and duration of treatment in
order to improve adherence and reduce the potential for incom-
plete treatment and development of resistance. As mentioned pre-
viously, the significance of the total cumulative primaquine dose
given, rather than the length of the course, is one avenue of investi-
gation. In areas where G6PD screening is present, using higher dos-
ing regimens over shorter time periods, if at least similarly effica-
cious, could improve adherence and reduce morbidity associated
with P vivax parasitaemia.
World Health Organization guidelines suggest a higher dosing reg-
imen of primaquine for the tropical, frequent-relapsing strain of P
vivax in East Asia and Oceania (WHO 2015), although the previous
Cochrane Review, Galappaththy 2013, did not find any trials assess-
ing this. Investigating the evidence base for this is therefore impor-
tant. The 2015 WHO guidelines also suggest an alternate dosing
regimen of weekly primaquine, which may be safer in patients with
G6PD deficiency. As the previous Cochrane Review included data
from only one trial assessing this, it is useful to investigate whether
there is further evidence to substantiate this guidance.
In this Cochrane Review, we have excluded comparisons between
blood-stage drug (chloroquine/ACT) with and without primaquine,
as the rationale for primaquine use has been sufficiently demon-
strated in a previous Cochrane Review (Galappaththy 2013). Simi-
larly, we have not included comparisons between different blood-
stage drugs in which the same dose of primaquine was used; an up-
date to an existing Cochrane Review, Gogtay 2013, is in progress
and will address this. However, we planned to stratify our results
according to partner drug, as there is increasing evidence that pri-
maquine is metabolized via the cytochrome P450 2D6 (CYP2D6)
pathway (Bennett 2013), and efficacy may thus be affected if the
blood-stage antimalarial drug is a CYP2D6 inhibitor (Baird 2018).
This review excluded comparisons of regimens that do not use the
control of the standard or high-standard regimen of 14 days of pri-
maquine. Also, it did not include comparisons of primaquine reg-
imens of 0.25 mg/kg/day for less than 14 days, as Galappaththy
2013 has already assessed these shorter regimens of the same daily
dose.
There is currently a lack of consensus among studies as to what
the minimum time frame for follow-up of relapse in P vivax malar-
ia should be. The WHO guidance on clinical trials in malaria sets
out standard follow-up for blood (or schizontal) stage infection as
28 days after treatment commencement, but has no clear defini-
tion on the follow-up period for radical cure in primaquine studies.
It states that "follow up varies from three months to a year in the
literature, and should be adapted to regional parasite characteris-
tics" (WHO 2009). In a recent review, John 2012 described relapse of
the tropical frequently relapsing strain of P vivax as typically three
weeks, but this varies according to blood-stage treatment: "three
weeks following quinine therapy" and "six to eight weeks follow-
ing chloroquine" (White 2011). With exposure to primaquine - even
if radical cure is not achieved - relapses may occur at longer inter-
vals (Sutanto 2013). In the Cochrane Review (Galappaththy 2013),
the follow-up period started 30 days after completing primaquine
treatment. Relapse is frequently defined as the presence of P vivax
parasites more than 28 to 30 days after the full course of primaquine
in people living in a non-endemic area (Looareesuwan 1997). Due to
the varying lengths of treatment and relapse time in P vivax malar-
ia, 28 days from treatment completion may not allow true assess-
ment of radical cure. It also makes assessment of the weekly pri-
maquine regimen difficult, as the follow-up time should start be-
fore the eight-week treatment course has finished. In this Cochrane
Review we planned to assess parasitaemia at 3, 6, and 12 months'
follow-up, in keeping with WHO guidance. We intended to describe
the length of follow-up across studies, and then group them into
meaningful lengths of follow-up, depending on the regimen.
We intended to answer the following questions by comparing the
new regimens to the standard 14-day regimen of primaquine (0.25
mg/kg/day; 15 mg adult dose) or the high-standard 14-day regimen
(0.5 mg/kg/day; 30 mg adult dose) recommended for East Asia/
Oceania.
• Is the high-standard 14-day regimen more efficacious and safer
compared to the standard 14-day course in all areas, or only in
areas where it is recommended (East Asia and Oceania)?• Are shorter, higher-dose regimens (0.5 mg/kg/day for 7 days) as
efficacious and safe as the standard 14-day regimen?• Are weekly dosing regimens (0.75 mg/kg or 45 mg adult dose/
week for 8 weeks) as efficacious and safe as the standard or high-
standard 14-day regimen?
O B J E C T I V E S
To assess the efficacy and safety of alternative primaquine regi-
mens for radical cure of P vivax malaria compared to the standard
or high-standard 14 days of primaquine (0.25 or 0.5 mg/kg/day), as
well as comparison of these two WHO-recommended regimens.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs). We excluded quasi-RCTs.
Types of participants
Adults and children with confirmed clinical and parasitological
(light microscopy or PCR, or both) diagnosis of P vivax malaria. We
included trials that excluded people with G6PD deficiency and tri-
als that included populations that had or had not been screened
for G6PD deficiency. People with mixed malaria infections were ex-
cluded.
Types of interventions
Intervention
Any regimen of either chloroquine or an artemisinin-based combi-
nation therapy (ACT) plus primaquine with any of the following.
• Daily doses higher than 0.25 mg/kg/day for 14 days.• Shorter regimens with the same total dose.• Weekly dosing regimens.
Control
WHO-defined standard regimen of 14 days of primaquine at 0.25
mg/kg/day (15 mg adult dose) in most areas, or high-standard reg-
imen of 0.5 mg/kg/day (30 mg adult dose) in East Asia and Oceania,
plus either chloroquine or an ACT.
We included comparisons between the two WHO recommended 14
day regimes (0.25mg/kg/day and 0.5mg/kg/day). We included tri-
als that used chloroquine or ACT as the treatment for blood-borne
infection, and we planned to stratify by the blood schizonticidal
agent.
Types of outcome measures
Primary outcomes• P vivax parasitaemia (detected by light microscopy or PCR, or
both) at 3, 6, and 12 months' follow-up. We planned to describe
this as recurrences of P vivax malaria due to the previously men-
tioned difficulties in distinguishing between relapse and re-in-
fection.
Secondary outcomes• P vivax parasitaemia (detected by light microscopy or PCR, or
both) at one to three months' follow-up.
Adverse events• Serious adverse events (fatal, life-threatening, or requiring hos-
pitalization).• Adverse events that result in discontinuation of treatment.• Events known to occur with primaquine (cyanosis, leucopenia,
methaemoglobinaemia, hypertension, cardiac arrhythmia, ab-
dominal pain, nausea, vomiting, or haemolysis) or those due to
a comparator drug used along with primaquine.• Anaemia or change in haemoglobin status.• Other adverse events.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, or in
progress).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Diseases
Group Specialized Register (17 December 2018); the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL, 2018, Issue 12, pub-
lished in the Cochrane Library); MEDLINE (PubMed, 1946 to 17 De-
cember 2018); Embase (Ovid, 1947 to 17 December 2018); and
LILACS (Bireme, 1982 to 17 December 2018). We also searched the
World Health Organization (WHO) International Clinical Trials Reg-
istry Platform (ICTRP; www.who.int/ictrp/), and ClinicalTrials.gov
(clinicaltrials.gov/ct2/home), for trials in progress, on 17 December
2018, using "primaquine" and "vivax" as search terms.
Searching other resources
We checked the reference lists of all studies identified by the above
methods for additional potentially relevant studies. We contacted
researchers working in the field and the WHO for unpublished and
ongoing trials. We also searched the reference lists and included
studies of the Cochrane Review by Galappaththy 2013.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and ab-
stracts of the search results to identify potentially eligible trials,
coding the articles as either 'retrieve' or 'do not retrieve'. We ob-
tained the full-text reports of potentially eligible trials and assessed
them for inclusion in the review using a predesigned eligibility form
based on the inclusion criteria. Any discrepancies were resolved
through discussion or by consulting a third review author if neces-
sary. Where necessary, we contacted the trial authors for clarifica-
tion of trial methods. We listed the excluded trials and the reasons
for their exclusion in a 'Characteristics of excluded studies' table.
Where there were multiple reports relating to the same trial, we
planned to include all reports and collate data. We detailed the trial
selection process in a PRISMA diagram.
Data extraction and management
Two review authors independently extracted data from the includ-
ed trials using a data extraction form designed specifically for this
review, in keeping with Cochrane guidance (Higgins 2011).
For each included trial we extracted a minimum of the following
data where available.
• Study design.• Endemicity/population demographics.• G6PD status of participants (known/unknown).• CYP2D6 status (if available).• Blood-stage antimalarial drug choice.• Dose/duration/timing of treatment arms.• Supervised or non-supervised therapy.• Duration of follow-up.• Adverse events.
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• Reported outcomes.
Any differences in data extraction were resolved through discus-
sion or by consulting a third review author if necessary. We entered
the extracted data into Review Manager 5 (RevMan 2014). Where
necessary, we contacted the authors of primary trials regarding
missing data or methodological details of the trial. We noted any
limitations in the included studies.
We grouped comparisons as illustrated in Table 1.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included trial using the Cochrane 'Risk of bias' assessment tool,
discussing any differences of opinion. In the case of missing or un-
clear information, we contacted the trial authors for clarification.
We summarized the results in the 'Risk of bias' tables in the 'Char-
acteristics of included studies' tables (Higgins 2011).
Measures of treatment eBect
For dichotomous data, we compared interventions using risk ratios
(RRs) to measure treatment effect. Where trial authors presented
data as odds ratios, we recalculated the effect. We defined statis-
tical significance as P < 0.05 and calculated 95% confidence inter-
vals (CIs) for all results. For comparable trials, we performed meta-
analyses if there were sufficient data.
Unit of analysis issues
We split trials that included more than two comparison groups and
analysed them as individual pair-wise comparisons. If there was
a shared control group, we split the control group so that partici-
pants were only counted once in the overall meta-analysis.
Dealing with missing data
We analysed missing data using available-case analysis if we judged
the trial to be at low risk of bias for incomplete outcome data. We at-
tempted to contact trial authors to obtain missing or unclear data.
If the missing data rendered the result uninterpretable, we exclud-
ed the data from meta-analyses and clearly stated the reason for
exclusion. If the missing data meant that results were interpretable
but likely to be at high risk of bias, we used imputation methods
to investigate the impact of the missing data. We analysed extract-
ed data on an intention-to-treat basis where there were no missing
data.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs. We also applied the
Chi2 test as a statistical test for the presence of heterogeneity, with
a P value of 0.10 used to indicate statistical significance, and we
computed the I2 statistic to quantify the percentage of the variabil-
ity in effect estimates that was due to heterogeneity rather than
sampling error (chance). We investigated possible causes of hetero-
geneity by subgroup analysis. If substantive heterogeneity persist-
ed, defined as an I2 statistic value of greater than 50%, we used a
random-effects meta-analysis.
Assessment of reporting biases
We planned to examine the likelihood of reporting bias using fun-
nel plots, however the number of included trials was insufficient to
permit this.
Data synthesis
We analysed the data using Review Manager 5 (RevMan 2014).
We assessed the certainty of the evidence for each outcome mea-
sure using the GRADE approach, and we constructed 'Summary
of findings' tables using GRADEpro GDT (GRADEpro GDT 2015). We
stratified results according to blood-stage partner drug (if differ-
ent blood-stage antimalarials were used, which only occurred for
one comparison). Length of follow-up varied with regimens and be-
tween studies. We described regimens and follow-up periods and
defined sensible groupings for follow-up. We also performed sub-
group analyses according to geographical region/endemicity and
directly observed therapy (DOT) or non-DOT. We stratified results by
length of follow-up. We had planned to perform a subgroup analy-
sis according to CYP2D6 status, however data were insufficient to
permit this.
Subgroup analysis and investigation of heterogeneity
We grouped the analysis by drug regimen. We described the inter-
ventions and outcomes in all included trials. We conducted an in-
ventory of length of follow-up against each drug regimen and then
grouped P vivax parasitaemia recurrence by appropriate groupings
for length of follow-up.
Sensitivity analysis
We planned to assess the risk of bias of studies that contributed da-
ta to the meta-analyses for the prespecified outcomes with sensi-
tivity analyses against concealment of allocation.
R E S U L T S
Description of studies
Results of the search
Our database search, conducted up to 17 December 2018, identi-
fied 251 studies (after removal of 3 duplicates). We excluded 214
articles during abstract screening, and selected 37 studies for full-
text review. We excluded 25 studies with reasons provided; identi-
fied two trials as ongoing; and included 10 studies in the review.
The search results are presented in a PRISMA diagram in Figure 2.
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Figure 2.   Study flow diagram.
 
Included studies
Although 10 studies (of 10 trials) met our inclusion criteria, one
study was deemed ineligible for data extraction and analysis. There
were only partially available results available in a conference ab-
stract for Chu 2016 THA, meaning that we could not assess risk of
bias or analyse results. We contacted the author for the full results
but this was declined pending future publication. We included nine
studies (of nine trials) in our quantitative analysis.
Four trials were conducted in South America: one in Colombia (Car-
mona-Fonseca 2009 COL), one in Brazil (Abdon 2001 BRA), and two
in Peru (Solari-Soto 2002 PER; Durand 2014 PER). Five trials were
conducted in Asia: one in Pakistan (Leslie 2008 PAK), one in Thai-
land (Bunnag 1994 THA), and three in India (Rajgor 2014 IND; Pareek
2015 IND; Saravu 2018 IND). All nine trials included data for adults,
and four trials included children under the age of 10 years (So-
lari-Soto 2002 PER; Leslie 2008 PAK; Carmona-Fonseca 2009 COL;
Durand 2014 PER). No trials had information on children under one
year old.
Seven trials excluded pregnant women, and two trials did not
specify whether or not pregnant women were included (Bunnag
1994 THA; Solari-Soto 2002 PER). Six trials specified that lactating
women were excluded, while the remaining three trials did not pro-
vide details regarding this (Bunnag 1994 THA; Solari-Soto 2002 PER;
Carmona-Fonseca 2009 COL). Only one trial included people with
G6PD deficiency (Leslie 2008 PAK). Six trials excluded people with
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G6PD deficiency (Bunnag 1994 THA; Carmona-Fonseca 2009 COL;
Durand 2014 PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018
IND), and two trials did not specify whether or not people with G6PD
deficiency were included (Abdon 2001 BRA; Solari-Soto 2002 PER).
All of the trials used microscopy for diagnosis of parasitaemia. Four
trials carried out PCR genotyping of vivax parasitaemia as well (Du-
rand 2014 PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018 IND).
Two trials used different doses or regimens of chloroquine within
trial arms, but as both confirmed that parasitaemia had resolved
following treatment, we still included them in the review (see Char-
acteristics of included studies) (Bunnag 1994 THA; Abdon 2001
BRA). None of the included trials described the CYP2D6 status of
participants.
Excluded studies
We excluded 25 studies during full-text screening; see details in
Characteristics of excluded studies.
Risk of bias in included studies
A summary of the 'Risk of bias' assessments is presented in Figure
3. Full details are shown in the Characteristics of included studies
tables.
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Figure 3.   ‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included
study.
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Allocation
Four trials described adequate methods of treatment randomiza-
tion and were judged to be at low risk of selection bias (Durand 2014
PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018 IND). We as-
sessed one trial as being at high risk of bias as it used two differ-
ent methods of randomization depending on location, using house
numbers or sequential patient numbers (Leslie 2008 PAK). Four tri-
als did not detail the randomization process (Bunnag 1994 THA; Ab-
don 2001 BRA; Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL).
Two trials used sealed envelopes to conceal allocation and so were
assessed as being at low risk of bias (Durand 2014 PER; Pareek 2015
IND). We assessed two trials with no concealment of treatment al-
location as at high risk of bias (Leslie 2008 PAK; Rajgor 2014 IND),
while five trials provided no information on whether or not alloca-
tion concealment was used(Bunnag 1994 THA; Abdon 2001 BRA; So-
lari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Saravu 2018 IND).
Blinding
Seven trials were open-label and were assessed as at high risk of
performance bias (Abdon 2001 BRA; Solari-Soto 2002 PER; Leslie
2008 PAK; Carmona-Fonseca 2009 COL; Durand 2014 PER; Rajgor
2014 IND; Saravu 2018 IND); two of these trials reported blinding of
the microscopists who analysed the blood work (Leslie 2008 PAK;
Rajgor 2014 IND). Two trials reported blinding of participants and
personnel and were classified as being at low risk of bias (Bunnag
1994 THA; Pareek 2015 IND).
Incomplete outcome data
Five trials had low rates of attrition with losses accounted for and
so were judged as at low risk of attrition bias (Abdon 2001 BRA;
Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Durand 2014
PER; Pareek 2015 IND). We assessed four trials as at high risk of at-
trition bias. Bunnag 1994 THA had unexplained, significant loss to
follow-up (more than three-quarters of participants by the end of
the trial), making the results uninterpretable. Leslie 2008 PAK had a
higher loss to follow-up in the intervention group compared to the
control group (6% loss versus 1% loss). Rajgor 2014 IND had a high
percentage of missing results at six months. Saravu 2018 IND had a
high percentage of loss to follow-up in both arms by six months.
Selective reporting
We judged four trials to have adequately reported on either pre-
specified or expected outcomes (Abdon 2001 BRA; Leslie 2008 PAK;
Durand 2014 PER; Saravu 2018 IND). Risk of reporting bias was un-
clear for five trials as no protocols were available (Bunnag 1994
THA; Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Rajgor
2014 IND; Chu 2016 THA). We assessed Pareek 2015 IND as being
at high risk of reporting bias because compliance was added as an
outcome, primaquine levels were not reported as planned, and PCR
results were not well-detailed.
Other potential sources of bias
We judged Pareek 2015 IND to be at high risk of other bias as it was
funded by the drug company that manufactured the primaquine
preparations, and the authors were employees of the company. We
assessed six trials as at low risk of other bias (Solari-Soto 2002 PER;
Leslie 2008 PAK; Carmona-Fonseca 2009 COL; Durand 2014 PER; Ra-
jgor 2014 IND; Saravu 2018 IND). We assessed two trials for which
funding was not detailed as at unclear risk of other bias (Bunnag
1994 THA; Abdon 2001 BRA).
EBects of interventions
See: Summary of findings for the main comparison ‘Summary of
findings' (main comparison); Summary of findings 2 ‘Summary of
findings' table 2; Summary of findings 3 ‘Summary of findings' ta-
ble 3
High-standard 14-day regimen versus standard 14-day
regimen
The WHO recommends higher doses of primaquine (0.5 mg/kg/
day) for 14 days in East Asia and Oceania. We intended to examine
whether this high-standard regimen was more efficacious in areas
where it is currently recommended (because of assumed resistance
- East Asia, Oceania) as well as in all other areas where resistance
is not thought to occur.
Two trials compared the high-standard 14-day course with the
standard (0.25 mg/kg/day) 14-day course, both carried out in
adults in India (Rajgor 2014 IND; Saravu 2018 IND). Both trials ex-
cluded pregnant/lactating and G6PD-deficient patients. In Rajgor
2014 IND, participants were treated with chloroquine, with the
primaquine regimen (which was supervised) given after comple-
tion of the chloroquine course. In Saravu 2018 IND, participants
were treated with either chloroquine or an ACT (artesunate with
doxycycline or artemether-lumefantrine), and (unsupervised) pri-
maquine was given after completion of the blood-stage treatment.
We planned to stratify results according to blood-stage treatment;
however, Saravu 2018 IND combined the results for both blood-
stage treatments, so we were unable to separate results according
to partner drug. Only the blood-stage drugs given to participants
who had recurrences were described. For this reason, results from
the two studies are not combined and are presented separately.
Eicacy
In Rajgor 2014 IND, 21 participants out of 317 in the high-standard
14-day group had a recurrence of vivax malaria compared with 26
out of 322 in the standard 14-day group at 6 months' follow-up,
giving an 18% reduction in recurrence of parasitaemia in the high-
standard group (risk ratio (RR) 0.82, 95% confidence intervals (CI)
0.47 to 1.43; 639 participants; very low-certainty evidence; Analy-
sis 1.1). Vivax malaria recurrences were also investigated by PCR to
determine whether they were true relapses or new infections. Af-
ter this adjustment, results showed an 83% increase in vivax malar-
ia cases in the high-standard group (RR 1.83, 95% CI 0.62 to 5.40;
Analysis 1.2).
Rajgor 2014 IND was at high risk of bias for allocation concealment.
However, as we chose not to combine the data with Saravu 2018
IND for this analysis, a sensitivity analysis could not be done.
In Saravu 2018 IND, 2 out of 18 participants in the high-standard
14-day group had a recurrence of P vivax malaria compared to 2
out of 20 in the standard 14-day group at 6 months' follow-up (RR
1.11, 95% CI 0.17 to 7.09; Analysis 1.1). Both of the recurrences in
the high-standard 14-day group were given chloroquine. Of the re-
currences in the standard 14-day group, one participant received
chloroquine and one participant received artesunate and doxycy-
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cline. Polymerase chain reaction genotyping suggested that all four
participants had true relapses of infection.
It should be noted that because Saravu 2018 IND was a small pilot
trial, if we had not stratified according to blood-stage treatment,
results would have been largely the same as for Rajgor 2014 IND
alone.
Adverse eects
In Rajgor 2014 IND there were no serious adverse events were re-
ported in either study arm (778 participants). In the high-standard
14-day group, 8 out of 380 participants discontinued treatment due
to adverse events, compared to 2 out of 398 in the standard 14-day
group (RR 4.19, 95% CI 0.90 to 19.60; 778 participants; very low-cer-
tainty evidence; Analysis 1.4). In the high-standard arm, 13 out of
380 participants experienced adverse events known to occur with
primaquine, compared to 5 out of 398 in the standard arm (RR 2.72,
95% CI 0.98 to 7.57; 778 participants; very low-certainty evidence;
Analysis 1.5). In the high-standard arm, 4 out of 380 participants
experienced adverse events known to occur with the blood-stage
antimalarial chloroquine, compared to 0 out of 398 in the stan-
dard group (RR 9.43, 95% CI 0.51 to 174.47; 778 participants; very
low-certainty evidence; Analysis 1.6). This could suggest a trend to-
wards a higher occurrence of adverse events in the high-standard
14-day regimen.
No significant adverse events were noted in either group in Saravu
2018 IND.
0.5 mg/kg/day for 7 days versus standard 14-day regimen
This comparison aimed to investigate whether shorter, higher-dose
regimens of primaquine over 7 days are as efficacious as standard
treatment over 14 days to determine whether the total dose rather
than the length of treatment is an important factor (total dose 210
mg).
Five trials in India and South America compared 0.5 mg/kg/day of
primaquine for 7 days versus the standard (0.25 mg/kg/day) 14-day
regimen (same total dose 210 mg) (Abdon 2001 BRA; Solari-Soto
2002 PER; Durand 2014 PER; Rajgor 2014 IND; Pareek 2015 IND). Pa-
reek 2015 IND used a sustained-release preparation of primaquine
in two of the study arms (0.5 mg/kg/day sustained release and 0.25
mg/kg/day sustained release) and standard primaquine at 0.25mg/
kg/day in a third arm. We included the 0.5 mg/kg/day sustained re-
lease in the analysis and combined the results with the standard
preparation at the same dose used for the other trials, but used on-
ly the standard-preparation group of 0.25 mg/kg/day in the study
as the control group and did not include the arm of 0.25mg/kg/day
sustained release preparation.
Three trials excluded people with G6PD deficiency, while two tri-
als did not provide this information (Bunnag 1994 THA; Solari-So-
to 2002 PER). All but one trial excluded women who were pregnant
or lactating (Solari-Soto 2002 PER did not provide details). Partici-
pants were a mixture of adults and children over one year old. All
trials used microscopy for diagnosis, and only Pareek 2015 IND did
not use supervised treatment. Two trials gave chloroquine and pri-
maquine courses simultaneously (Abdon 2001 BRA; Durand 2014
PER), while the other three trials administered primaquine follow-
ing the chloroquine course. No trials stratified by age, so results
were combined.
Eicacy
There was minimal difference in the number of malaria recurrences
between groups at 6 to 7 months' follow-up (RR 0.96, 95% CI 0.66 to
1.39; 1211 participants; low-certainty evidence; Analysis 2.1). One
trial only followed participants for two months (Solari-Soto 2002
PER), and so was not part of the main analysis.
We had planned to perform a sensitivity analysis based on risk of
bias for allocation concealment (which would have involved re-
moving Rajgor 2014 IND from the meta-analysis), but we decided
that as the remaining trials were all at high risk of bias for blinding
and thus quality was generally low, we would not conduct a sensi-
tivity analysis but address these issues in our GRADE assessment.
Two trials PCR-adjusted their results to differentiate between re-
lapses and new infections at 6 to 7 months' follow-up. In Durand
2014 PER, PCR-adjusted results showed a 31% reduction in re-
currence (24% reduction with light microscopy) with the regimen
of 0.5 mg/kg/day for 7 days compared with the standard 14-day
course, while in Rajgor 2014 IND, PCR-adjusted results showed a
159% increase in recurrence (25% increase in recurrence with light
microscopy) with the regimen of 0.5 mg/kg/day for 7 days com-
pared to the standard 14-day regimen (Analysis 2.2). We decided
that these results could not be combined in a meta-analysis, as PCR
techniques can differ, and there were high levels of heterogeneity.
We performed a subgroup analysis according to geographic region
(Analysis 2.3). For trials in South America, the regimen of 0.5 mg/kg/
day for 7 days led to a 30% reduction in P vivax recurrences com-
pared to a 19% increase in recurrences for trials in Asia, although
confidence intervals were wide and included no effect for both sub-
groups (South America: RR 0.70, 95% CI 0.39 to 1.26; Asia: RR 1.19,
95% CI 0.73 to 1.94). Only one trial did not use directly observed
therapy (DOT) (Pareek 2015 IND). Subgroup analysis (Analysis 2.4)
showed that with DOT there was minimal difference in recurrences
at 6 to 7 months between treatment regimens (RR 0.98, 95% CI 0.67
to 1.43) compared to a reduction of about half of recurrences with
the regimen of 0.5 mg/kg/day for 7 days when treatment was not
supervised (RR 0.48, 95% CI 0.04 to 5.20).
Adverse eects
No serious adverse events were reported in either group (1427 par-
ticipants). The number of participants experiencing adverse events
leading to discontinuation of treatment was similar in both groups
(RR 1.04, 95% CI 0.15 to 7.38; 1154 participants; Analysis 2.6), as
were adverse events known to occur with primaquine (RR 1.06, 95%
CI 0.64 to 1.76; 1154 participants; Analysis 2.7). One trial reported on
change in haemoglobin status (Pareek 2015 IND), with 1 participant
out of 120 in the group receiving 0.5 mg/kg/day for 7 days becoming
anaemic, versus no participants out of 120 in the standard 14-day
regimen group (RR 3.0, 95% CI 0.51 to 174.01; 240 participants; very
low-certainty evidence; Analysis 2.8). Only one study reported on
adverse events known to occur with chloroquine (Rajgor 2014 IND),
with more occurring in the group receiving 0.5 mg/kg/day for 7 days
than the standard 14-day group (RR 9.40, 95% CI 0.51 to 174.01; 779
participants; very low-certainty evidence; Analysis 2.9).
0.75 mg/kg primaquine/week for 8 weeks versus high-
standard 14-day regimen
This comparison aimed to investigate whether a higher once-week-
ly dosing regimen, which may be more beneficial for people with
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G6PD deficiency, was as efficacious as the high-standard 14-day
regimen.
One trial compared weekly 0.75 mg/kg primaquine (45 mg adult
dose) for 8 weeks with the high-standard 14-day regimen (0.5 mg/
kg/day) (Leslie 2008 PAK). G6PD-deficient participants were not
randomized but were included in the weekly group, although there
only was one G6PD-deficient person included. Pregnant and lactat-
ing women were excluded. Treatment was supervised. It was not
specified whether chloroquine and primaquine were given concur-
rently.
Eicacy
Recurrences were more common in the weekly group at 8 months'
follow-up (RR 7.0, 95% CI 0.38 to 127.32; 126 participants; Analysis
3.1). Recurrences remained more common in the weekly group at
11 months' follow-up (RR 3.18, 95% CI 0.37 to 27.6; 122 participants;
Analysis 3.1). Leslie 2008 PAK was at high risk of bias for allocation
concealment, but a sensitivity analysis could not be done as it was
the only trial found for this comparison.
Adverse eects
No serious adverse events were reported in either study arm (Analy-
sis 3.2). No participants had anaemia defined as haemoglobin less
than 7 g/dL (Analysis 3.3).
Other regimens
0.375 mg/kg/day for 14 days versus standard 14-day regimen
Bunnag 1994 THA compared 0.375 mg/kg/day (adult dose 22.5 mg)
primaquine daily for 14 days with the standard regimen of 0.25 mg/
kg/day for 14 days. There was a high loss to follow-up, with 167 par-
ticipants enrolled and only 38 completing 18 months' follow-up, al-
though the loss was equal in both groups at the end of follow-up. At
6 months' follow-up there were no episodes of P vivax in the exper-
imental group (0/40) and two recurrences in the standard-regimen
group (2/33) (RR 0.17, 95% CI 0.01 to 3.34; 73 participants; Analy-
sis 4.1), although only about half of enrolled participants were fol-
lowed up at this time point. No further recurrences were described
in either group up to the end of follow-up at 18 months, but as de-
scribed, the high level of unexplained dropout makes interpreta-
tion difficult.
No formal assessment of adverse events was reported, but it is
mentioned in the study narrative that there was no drop in haema-
tocrit or haemoglobinuria in either group.
1.17 mg/kg/day for 3 days versus standard 14-day regimen
One trial delivered the total dose of primaquine (1.17 mg/kg/day or
70 mg adult dose, total dose 210 mg) over 3 days versus the stan-
dard (0.25 mg/kg/day) 14-day regimen (Carmona-Fonseca 2009
COL). Recurrences of P vivax malaria were more common in the
group receiving 1.17 mg/kg/day for 3 days than in the standard 14-
day group at 4 months' follow-up (RR 3.88, 95% CI 2.11 to 7.11; 129
participants; Analysis 5.1).
Adverse events were not reported, although it was noted that there
were no serious adverse events from co-administering primaquine
and chloroquine.
1 mg/kg/day for 7 days versus high-standard 14-day regimen
This comparison aimed to investigate whether shorter, higher dos-
es of primaquine over 7 days are as effective as the high-standard
14-day regimen to determine whether the total dose rather than the
length of treatment is the important factor for East Asia and Ocea-
nia regimen (total dose 420 mg primaquine). Only one included trial
compared 1 mg/kg/day (adult dose 60 mg) of primaquine for 7 days
with the high-standard 14-day course (0.5 mg/kg/day) (Chu 2016
THA), administering the regimen with either chloroquine or an ACT
(4 arms). Results are still awaited, but a conference report of the tri-
al reports that out of 680 participants there was no difference be-
tween the two regimens. No further details are currently available.
D I S C U S S I O N
Summary of main results
High-standard 14-day regimen versus standard 14-day
regimen
See Summary of findings 2
We included 2 RCTs that compared 0.5 mg/kg/day primaquine (dai-
ly adult dose 30 mg) for 14 days with 0.25 mg/kg/day (daily adult
dose 15 mg) for 14 days, both conducted in India. People with G6PD
deficiency and pregnant or lactating women were excluded. One
trial did not account for whether participants were given chloro-
quine or an ACT for blood-stage treatment. We do not know if there
is any difference in P vivax recurrences at 6 months with the high-
standard 14-day course compared to the standard 14-day course
when given with chloroquine (very low-certainty evidence). We do
not know if there is any difference in P vivax relapses at 6 months
with the high-standard 14-day course compared to the standard 14-
day course when given with chloroquine or an ACT (very low-cer-
tainty evidence).
No serious events were reported in either trial. We do not know
whether there is a difference in adverse events between the high-
standard 14-day course and the standard 14-day course (very low-
certainty evidence).
0.5 mg/kg/day for 7 days versus standard 14-day regimen
See Summary of findings for the main comparison
We included 5 RCTs that compared 0.5 mg/kg/day (adult dose 30
mg) primaquine for 7 days with the standard 14-day regimen (0.25
mg/kg/day). There may be little or no difference in P vivax recur-
rences at 6 to 7 months when using the same total dose (210 mg)
over 7 days as compared to 14 days (low-certainty evidence). No
serious adverse events were reported. There may be little or no
difference in the number of adverse events known to occur with
primaquine when using the shorter regimen as compared to the
longer regimen (low-certainty evidence).
We do not know whether there is any difference in the frequency
of anaemia or discontinuation of treatment between groups (very
low-certainty evidence). Three trials excluded people with G6PD
deficiency, and two did not provide this information, so we do not
know the effect of the higher daily dose regimen in this group. Preg-
nant and lactating women were either excluded or this information
was not provided.
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0.75 mg/kg primaquine/week for 8 weeks versus high-
standard 14-day regimen
See Summary of findings 3
We included 1 RCT that compared 0.75 mg/kg (daily adult dose 45
mg) weekly primaquine for 8 weeks with the high-standard 14-day
regimen (0.5 mg/kg/day, daily adult dose 30 mg). G6PD-deficient
participants were not randomized but were included in the week-
ly primaquine group. Only one G6PD-deficient participant was de-
tected during the trial and was included in the weekly group. We do
not know whether weekly primaquine reduces recurrence of P vivax
compared to the high-standard 14-day regimen at 8 to 11 months'
follow-up (very low-certainty evidence).
No serious adverse events and no episodes of anaemia were report-
ed.
Some other included trials evaluated alternative regimens and dos-
es of primaquine, but these regimens have not been widely used,
and the evidence available from stand-alone trials was of very low
certainty.
Overall completeness and applicability of evidence
We initially thought we could evaluate whether the high-standard
14-day regimen (0.5 mg/kg/day) was more effective in all areas
rather than just areas where recommended by the WHO due to
reported resistance or strain differences (East Asia and Oceania)
(WHO 2015). However, we only found two trials that compared
the high standard 14-day regimen to the standard 14-day regimen,
both of which were conducted in India. A recent retrospective case
review in French Guiana (also an area where the high-standard
regimen is not currently recommended) found that recurrences
were similar in both standard and high-standard 14-day regimens
(Valdes 2018). We did not find any RCTs that evaluated whether
the high-standard 14-day regimen was more effective compared to
the standard 14-day regimen for the tropical, frequently relapsing
strain of P vivax in East Asia and Oceania, so we are unable to com-
ment on its efficacy.
A difficulty encountered in including and comparing studies was
the variation in dosing and length of follow-up in studies.
In general, there were few well-conducted RCTs that used an evi-
dence-based standard primaquine regimen (15 mg/kg/day for 14
days) as a comparator. Some trials used the high-standard 0.5 mg/
kg/day for 14 days regimen as a comparator, which is recommend-
ed by the WHO in East Asia and Oceania, which is why we included
these trials. However, there is limited clear evidence in this review
for the increased high-standard 14-day regimen. We found two ran-
domized clinical trials that compared its efficacy to the standard
regimen, both of which were conducted in India (Rajgor 2014 IND;
Saravu 2018 IND), where the regimen is not recommended.
We also found that trials continue to be conducted where place-
bo is used instead of an alternative primaquine regimen, which is
contrary to the evidence available demonstrating its superiority for
reducing recurrences (Galappaththy 2013). This may be because
there is continued reluctance to use primaquine in some national
programmes.
We excluded studies where individuals had mixed malaria infec-
tions so as to assess the efficacy of treatment on P vivax malaria
alone. Areas endemic for P vivax malaria may also be co-endemic
for P falciparum or Plasmodium ovale infection, or both. However,
it should be noted that as part of our screening process we did not
identify any studies where participants with mixed malaria were in-
cluded, so we do not think that narrowing our search criteria im-
pacted the directness of our results.
Although the evidence is currently of low certainty, it does appear
that using 0.5 mg/kg/day with the same total dose (210 mg) over 7
days may be non-inferior to the regimen of 0.25 mg/kg/day for 14
days. It may be that these shorter regimens promote course com-
pletion. Although no serious adverse events were reported due to
few reported events for any other adverse effects, it is difficult to
draw conclusions as to whether there may be increased adverse
events for this higher dosing until more data are available. This
higher-dose regimen was not tested in G6PD-deficient patients in
any of the RCTs meeting our inclusion criteria. This remains a con-
cern in settings where testing is not available.
There was a general lack of detailed safety data for trials, which
is interesting given that safety is a particular concern with pri-
maquine use. Only one included RCT investigated the weekly pri-
maquine regimen that is currently recommended by WHO for
G6PD-deficient individuals, and only one G6PD-deficient partici-
pant was actually included in the treatment group.
Certainty of the evidence
The overall certainty of evidence for all of the outcomes was either
low or very low. All results were downgraded for imprecision due to
wide CIs for all of the meta-analyses performed.
The efficacy comparison for the high-standard 14-day regimen ver-
sus the standard 14-day regimen was also downgraded for indirect-
ness. Results were based on two trials in adults in India (Rajgor 2014
IND; Saravu 2018 IND). Rajgor 2014 IND was at risk of bias as there
was no allocation concealment and unexplained loss to follow-up;
this study also contributed most to the meta-analysis for the com-
parison of 0.5 mg/kg/day for 7 days versus standard 14-day regi-
men, so this study was also downgraded. Saravu 2018 IND was a
small pilot study where participants were given either chloroquine
or an ACT for the blood stage, and which blood-stage treatment
they were given was not stated. Saravu 2018 IND was downgraded
for imprecision, indirectness, and risk of bias (not blinded and high
rate of loss to follow-up).
We downgraded the comparison of 0.75 mg/kg weekly primaquine
versus high-standard 14-day regimen for indirectness as it was
based on just one study conducted in Pakistan (Leslie 2008 PAK),
with only one G6PD-deficient patient participating. Leslie 2008 PAK
was at risk of bias due to the randomization process used, lack of
allocation concealment, and incomplete outcome data. We down-
graded efficacy outcomes for this comparison for serious impreci-
sion due to few events and very wide CIs.
Potential biases in the review process
The strictness of our inclusion criteria to not include trials where
the total dose was less than the total dose of the standard regimen
and the necessity of having the comparison arm be one of the WHO-
recommended regimens may have meant that some relevant com-
parisons were excluded.
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We changed the protocol to include the high-standard 14-day regi-
men that WHO recommends in East Asia and Oceania as a control
regimen, as we realized that some trials had used this as the com-
parator, and we felt that these comparisons were useful. However,
this may have introduced bias, as per our results the evidence base
for RCTs showing the efficacy of this regimen is limited.
The difficulty in determining between relapse and re-infection with
P vivax remains a recognized challenge for assessing the efficacy of
drugs for radical cure.
Agreements and disagreements with other studies or
reviews
Our findings that 210 mg over 7 days may be as efficacious as 210
mg over 14 days are similar to the findings of other systematic re-
views that examined both randomized and non-randomized stud-
ies (Carmona-Fonseca 2015; Zuluaga-Idarraga 2015). Other reviews
also commented on the difficulty of comparing results due to the
varying treatment regimens and length of follow-up used in clinical
trials (John 2012; Carmona-Fonseca 2015; Zuluaga-Idarraga 2015).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Although limited data were available, no difference was detected
for efficacy between the regimen of 0.5 mg/kg/day for 7 days and
the standard (0.25 mg/kg/day) 14-day regimen in G6PD-normal pa-
tients.
No serious adverse events were reported in G6PD-normal patients
taking 0.5 mg/kg/day of primaquine.
Implications for research
Further high-quality randomized controlled trials are needed with
more standardized comparison regimens and length of follow-up,
in particular investigating the use of the high-standard 14-day reg-
imen, same total dose over 7 days, and weekly regimens in G6PD-
deficient patients. Trials such as IMPROV will help resolve some of
the uncertainties.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods RCT
July 1994 to June 1995
Participants 120 participants enrolled.
Inclusion criteria:
• Confirmed parasitological diagnosis for P vivax malaria.• Age older than 12 years.• Staying in Belém (study area) until the end of the follow-up period (180 days).
Exclusion criteria
• Pregnant and nursing mothers were excluded.• Patients who used antimalarials at least 2 weeks prior to the start of current treatment.• Carriers of mixed malaria.
Diagnosis: microscopy
G6PD status not stated
No details CYP2D6 status.
Interventions • Chloroquine 10 mg/kg single dose + primaquine 0.5 mg/kg/day for 7 days.• Chloroquine 150 mg (25 mg/kg total dose) over 3 days, 10 mg/kg day 1, 7.5 mg/kg days 2 and 3 +
primaquine 15 mg/day 14 days.
(Additional arm chloroquine 10 mg/kg + primaquine 0.5 mg/kg for 5 days not included as total dose
(150 mg) less than standard treatment (210 mg))
Although different doses of chloroquine in the 2 arms, all participants had negative parasitaemia with-
in 72 hours.
Primaquine and chloroquine given concurrently.
Supervised treatment.
Outcomes • Relapse.• Safety.
Abdon 2001 BRA 
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Follow-up 180 days
Notes Location: Belém, state of Pará, Brazil
Setting: not stated
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details supplied on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details supplied on allocation.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk One loss to follow-up as moved out of area.
Selective reporting (re-
porting bias)
Low risk Unable to find protocol but relapse and standard errors (SEs) reported as
would be expected.
Other bias Unclear risk Funding not stated.
Abdon 2001 BRA  (Continued)
 
 
Methods RCT
Dates not provided.
Participants 167 participants enrolled.
Inclusion criteria:
• 15 to 60 years.
Exclusion criteria:
• History of previous treatment.• G6PD deficiency.• Mixed infections.
Diagnosis: microscopy
No details on pregnant/breastfeeding women.
Bunnag 1994 THA 
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No details CYP2D6 status.
Interventions • Chloroquine + 22.5 mg/day primaquine for 14 days.• Chloroquine + 15 mg/day primaquine for 14 days.
Open randomization to chloroquine treatment – either 300 mg or 450 mg on day 1 of admission. Re-al-
located after recovery of acute symptoms (double-blind RCT). Chloroquine course completed and para-
sitological clearance confirmed prior to randomization to primaquine group (exact time between treat-
ment courses not specified).
Supervised treatment in hospital.
Outcomes • Relapse.• Safety.
Follow-up 6 months
Notes Location: Thailand
Setting: not stated
Funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk 1st step chloroquine is open randomization, then PQ stage randomized. No de-
tails on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Reported as double-blind.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Reported as double-blind.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Unexplained high loss to follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol.
Other bias Unclear risk Funding not disclosed.
Bunnag 1994 THA  (Continued)
 
 
Methods RCT
September 2003 to September 2006
Carmona-Fonseca 2009 COL 
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Participants 133 patients enrolled across 2 arms (total 188 counting arms not included in review)
Inclusion criteria:
• Age > 2 years.• P vivax parasitaemia of > 1000 asexual forms/L.• Willingness to participate.• A normal quantitative G6PD screening test was required for those administered > 0.25 mg/kg/day pri-
maquine base, and only individuals with normal G6PD levels were included in the study.
Exclusion criteria:
• Pregnant women.• Those with associated acute infectious diseases.• A history of antimalarials intake during the previous 2 weeks.• Presence of diarrhoea or vomiting (> 5 episodes in 24 hours).• Symptoms or signs of severe malaria (according to WHO 2006).• Hypersensitivity to antimalarials or severe undernutrition.• Exclusion from the study also followed intake of any antimalarial different from those provided by the
researchers.• Failure to attend follow-up appointments.• Treatment failure during the primary episode (first 28 days of follow-up).• Consent withdrawal.
Diagnosis: microscopy
No details CYP2D6 status or breastfeeding mothers.
Interventions • Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 1.17 mg/kg/day for 3 days (total
210 mg).• Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 0.25 mg/kg/day for 14 days.
(Additional arms: 0.83 mg/kg day for 3 days (total dose 149.4 mg) and 0.58 mg/kg day for 3 days (total
dose 104.4 mg) not included as total dose less than standard treatment)
Primaquine given simultaneously with chloroquine.
Supervised treatment.
Outcomes • Recurrence of P vivax malaria (parasitaemia after day 28).
Follow-up 120 days
Notes Location: Colombia
Setting: patients that attended the local health clinics in Turbo and El Bagre
Funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Details of randomization not given.
Allocation concealment
(selection bias)
Unclear risk No details supplied.
Carmona-Fonseca 2009 COL  (Continued)
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
30
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No mention on blinding in blood smear assessment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 2 lost per group, no explanations given, but less than 5% of total across
groups.
Selective reporting (re-
porting bias)
Unclear risk Protocol not found. No safety data were provided (which might have been ex-
pected to have been provided).
Other bias Low risk Looks like government funding.
Carmona-Fonseca 2009 COL  (Continued)
 
 
Methods RCT
Participants 680 enrolled.
G6PD normal.
No further details
Interventions • Chloroquine + primaquine 7 days (1 mg/kg/day).• Chloroquine + primaquine 14 days (0.5 mg/kg/day).• Dihydroartemisinin-piperaquine + primaquine 7 days (1 mg/kg/day).• Dihydroartemisinin-piperaquine + primaquine 14 days (0.5 mg/kg/day).
No further details
Outcomes • Relapse.
Follow-up: 1 year
Notes Location: Thailand
Setting: no details
Funding: no details
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details.
Allocation concealment
(selection bias)
Unclear risk No details.
Chu 2016 THA 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No details.
Selective reporting (re-
porting bias)
Unclear risk No details.
Other bias Unclear risk No details.
Chu 2016 THA  (Continued)
 
 
Methods RCT
March 2006 to August 2008
Participants 360 participants
Inclusion criteria:
• Microscopy-confirmed diagnosis of monoinfection with P vivax between 250 and 100,000 asexual par-
asites/mL (determined by microscopic examination of thick and thin peripheral blood smears).• Fever defined as axillary temperature 37.5 °C or history of fever, or both.• > 1 year old.
Exclusion criteria:
• Pregnant and lactating women.• Patients with chronic illnesses.• Patients with symptoms of severe malaria.• Patients with G6PD deficiency.
Diagnosis: light microscopy
Parasite genotyping with PCR also performed - 5 microsatellite loci used to determine whether homol-
ogous relapse.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.
(Additional arm of chloroquine + primaquine 0.5 mg/kg/day for 5 days excluded as total dose 150 mg,
which was less than standard treatment.)
Supervised.
Primaquine administered concurrently with chloroquine.
Outcomes • Relapse between days 35 and 210.• Relapses (homologous only).
Durand 2014 PER 
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Follow-up: 210 days
Notes Location: Peru
Setting: Padre Cocha and the San Juan Health Centers and Santa Clara Health Center The periphery of
the city of Iquitos, which is located on the river bank of the Amazon River and is the largest city in the
Peruvian rainforest
Funding: the US Department of Defense Global Emerging Infections Surveillance and Response Sys-
tem (DoD-GEIS), the National Institute of Health of Peru, and the Pan-American Health Organization/US
Agency for International Development (PAHO-USAID) Americas Malaria Initiative/Amazonic Network of
Antimalarial Drug Resistance, AMI/RAVREDA project
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomization table.
Allocation concealment
(selection bias)
Low risk The treatment allocation for each participant was placed in a sealed envelope,
kept in an orderly manner, and opened only at the time of enrolment of a new
participant to prevent selection bias by study physicians.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label – no mention of blood smear blinding.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 8% to 10% loss following randomization, but all accounted for.
Selective reporting (re-
porting bias)
Low risk Study protocol registered. Unable to find outcomes in protocol, but expected
outcomes were reported on.
Other bias Low risk We did not detect any other sources of bias.
Durand 2014 PER  (Continued)
 
 
Methods RCT
September 2004 to July 2006
Participants 129 Afgan refugees
Inclusion criteria:
• Patients diagnosed with P vivax parasitaemia at study basic health units (BHUs).• Patients over 3 years of age.• Patient permanently resident in the village.
Exclusion criteria:
Leslie 2008 PAK 
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• Pregnancy or lactation.• Severe clinical anaemia (7 g/dL).• P falciparum or P vivax (mixed infections), or both.• Intake of any antimalarial drug in the 2 weeks prior to consultation.• Patients unavailable for the duration of follow-up (11 months).• Patients with concomitant infections or disease likely to mask treatment response.
Diagnosis: microscopy
Interventions • Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.75 mg/kg once weekly for 8
weeks.• Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.5 mg/kg/day for 14 days.
(Additional arm chloroquine + weekly placebo not included)
Supervised.
Not specified whether primaquine given concurrently with chloroquine.
Outcomes • P vivax malaria relapse.• The number of subsequent episodes and anaemia rates during and up to 2 weeks post-treatment as
well as any notable adverse events.
Follow-up: 9 months (11 months participation: 8 weeks treatment + 9 months follow-up)
Notes Location: Pakistan
Setting: Adizai, Baghicha, and Khagan villages, close to Peshawar, Northwest Frontier Province, Pak-
istan where Afghan refugees have been resident for more than 20 years
Funding: UNDP/World Bank/WHO Special Program for Research in Tropical Diseases; Gates Malaria
Partnership)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Two randomization methods were used. In Baghicha and Khagan villages, par-
ticipants were randomized by household, whereas in Adizai, randomization
was at the individual level. Randomization lists for each village were generat-
ed using a random number list (MS Excel, Microsoft Corp, Seattle, USA) by staE
not involved in patient recruitment. Participants were randomized on enrol-
ment by study staE in the BHUs based on house number or sequential patient
numbers, depending on the study site.
Allocation concealment
(selection bias)
High risk Participants were randomized on enrolment by study staE in the BHUs based
on house number or sequential patient numbers, depending on the study site.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Blood slides were double-read by 2 microscopists working independently, who
were blinded to the other's result.
Incomplete outcome data
(attrition bias) 
High risk Higher loss to follow-up in intervention group (6% to 8% versus 1% to 1.8%).
Leslie 2008 PAK  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Low risk Trial protocol available, all planned outcomes reported on.
Other bias Low risk We did not detect any other sources of bias.
Leslie 2008 PAK  (Continued)
 
 
Methods RCT
Participants 358 participants
Inclusion criteria:
• Patients of either sex.• Aged between 18 and 65 years.• Body weight > 40 kg.• Microscopically confirmed P vivax malaria with ≥ 1000 asexual parasites/µL of blood.• Axillary temperature ≥ 37.5°C (≥ 99.5°F).• Presence of at least 5 of the following signs and symptoms of uncomplicated malaria: chills, nausea,
vomiting, headache, malaise, diarrhoea, anorexia, abdominal cramps, myalgia, and arthralgia.
Exclusion criteria:
• Mixed malarial infections.• Severe or complicated malaria (as defined by the WHO).• G6PD deficiency.• Any other significant concomitant illness.• Patients with history of dark urine or significant haemoglobinuria related to previous primaquine
treatment or those with history of methaemoglobinaemia.• Patients with protracted vomiting and oliguria.• Those with underlying condition compromising bone marrow function or having a tendency to gran-
ulocytopenia.• Patients taking cardioactive drug or potentially haemolytic drugs or drugs that could interact with
study drugs.• Patients having history of hypersensitivity to any of the study-related drugs.• Those on another investigational drug.• History/presence of substance abuse.• Pregnant or lactating women or women of childbearing potential not using medically accepted means
of birth control.
Diagnosis: microscopy
Interventions • Chloroquine (3-day course, dose not specified) + primaquine 30 mg sustained release 7 days.• Chloroquine (3-day course, dose not specified) + primaquine 15 mg 14 days.
(Additional arm of chloroquine + primaquine 15 mg sustained release for 14 days not included in re-
view)
Primaquine given following completion of chloroquine course.
Not supervised.
Outcomes • Relapse.• Compliance.
Pareek 2015 IND 
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
35
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Safety.
PCR genotyping done to see if true relapse (no details on genotyping method).
Follow-up: 5 months (6 months participation)
Notes Location: India
Setting: multicentre, no details as to centres involved
Funding: funded by drug manufacturer Ipca Laboratories Ltd. Anil Pareek and Nitin Chandurkar are the
employees of Ipca Laboratories Ltd who sponsored this trial.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization codes were generated using computer-generated block ran-
domization method.
Allocation concealment
(selection bias)
Low risk Patient-specific sealed boxes of medicine were provided to each study site.
(Sequentially numbered, sealed, opaque envelopes (from protocol)).
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blind, double-dummy.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details as to whether microscopy was blinded or whether there was double
reading of smears.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Loss to follow-up equal between groups. Relapses counted as discontinued
patients, but numbers provided so can be assessed.
Selective reporting (re-
porting bias)
High risk Compliance added as an outcome, but original outcomes also reported on.
Not clear why they have concluded that compliance increased with SR, as par-
ticipants had to take 3 sets of pills as did those who took dummy versions, so
all participants took 3 sets of drugs.
No measurement of levels of PQ (pharmacokinetics), although states that PQ
SR should have therapeutic concentration over 24 hours as part of the con-
cept.
PCR results are not well-detailed.
Other bias High risk The study was sponsored by Ipca Laboratories Ltd, who manufactures the
drugs, and the principal investigators are employees of the company.
Pareek 2015 IND  (Continued)
 
 
Methods RCT
August 2001 to February 2004
Participants 1159 participants enrolled.
Rajgor 2014 IND 
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Inclusion criteria:
• Adult patients, male and female (18 years of age or older).• Peripheral blood smear diagnosis of P vivax.• Willing to undergo hospitalization for the entire duration of primaquine treatment.• Willing to provide informed consent.• Willing to undergo investigations and come for regular follow-up.• Normal G6PD.• Haemoglobin ≥ 10 g/dL.
Exclusion criteria:
• Mixed infection with P falciparum.• Pregnancy and lactation.• Evidence of significant hepatic, renal, or cardiac disease as diagnosed by history, clinical examination,
and laboratory tests whenever necessary.• Any other condition that would interfere with patient’s participation in the study or compliance with
the treatment.
Diagnosis: microscopy
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 15 mg/day 14 days.
(Additional no-primaquine arm not included in analysis)
Supervised treatment.
Primquine treatment commenced after chloroquine treatment (day 4).
Outcomes • Recurrence of vivax malaria.• Safety.
Follow-up: 6 months
The secondary outcome also included comparison of number of participants classified as relapse and
re-infection by the 3 methods to determine the concordance between the methods used and the genet-
ic diversity observed based on PCR sequencing method. The cases of recurrence were classified as re-
lapse or re-infection based on the 3 methods, the month of recurrence, and the 2 genotyping methods:
PCR-RFLP and PCR sequencing.
Notes Location: Mumbai, India
Setting: inpatient assessment in Mumbai
Funding: Indian Council of Medical Research
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A simple, computer-generated randomization scheme was used for the ran-
domization of participants into the 3 PQ regimen groups.
Allocation concealment
(selection bias)
High risk This was an open-label study, and no concealment of treatment allocation was
followed.
Rajgor 2014 IND  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Although the study was not blinded in terms of treatment administration, the
person seeing the slides and carrying out other outcome assessments was
blinded to the treatment group by coding of the samples.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High percentage of participants not completing 6 months' follow-up across all
groups. Minimal explanation for discontinuation of participants.
Selective reporting (re-
porting bias)
Unclear risk No registered protocol found - reported on expected outcomes of efficacy and
adverse effects. Trial carried out 2001 to 2004 but not published until 2014.
Other bias Low risk We did not detect any other sources of bias.
Rajgor 2014 IND  (Continued)
 
 
Methods RCT, open-label, pilot study
March 2017 to August 2017
Participants 50 participants enrolled.
Patients presenting to Kasturba Hospital, Manipal and Dr TMA Pai Hospital, Udupi, India
Inclusion criteria:
• P vivax malaria monoinfection.• Age 18 years and over.• Fever > 37.5°C tympanic or oral, or a history of fever within previous 3 days.• Willing to give informed consent.
Exclusion criteria:
• Pregnant or lactating, or both.• Patients with G6PD deficiency.• Mixed infection with P vivax and P falciparum.
Primaquine given after blood-stage treatment.
Diagnosis: microscopy, but PCR also performed to genotype recurrences
No details CYP2D6
Interventions Blood-stage treatment: either CQ or ACT (artesunate with doxycycline or artemether-lumefantrine as
per the treating clinician’s judgement of severity)
• Primaquine 0.5 mg/kg/day for 14 days• Primaquine 0.25 mg/kg/day for 14 days
Drug therapy not supervised.
Outcomes 1. Recurrence
(2. Primaquine levels in the blood at 7 days)
Saravu 2018 IND 
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Follow-up 6 months
Notes Location: Udupi district of Karnataka State, India
Setting: typical tropical climatic conditions. Malaria incidence throughout the year with peaks around
June to July. Urban and rural settings in catchment area.
Source of funding: seed Grant Award from Manipal McGill Center for Infectious Diseases
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization – 5 blocks of 10, randomization within each block done
by a lottery method.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High percentage of loss to follow-up by 6 months in both arms – results diffi-
cult to interpret.
Selective reporting (re-
porting bias)
Low risk Outcomes reported as per protocol.
Other bias Low risk Supported by a seed Grant Award from Manipal McGill Center for Infectious
Diseases, MAHE, Manipal.
Saravu 2018 IND  (Continued)
 
 
Methods RCT
October 1998 to January 1999
Participants 60 participants enrolled.
Inclusion criteria:
• Confirmed diagnosis of P vivax malaria (febrile and positive P vivax blood smear).
Exclusion criteria:
• Patients who had received antimalarial medication in the 4 weeks prior to diagnosis.• Children under 5 years.• Patients with severe concomitant diseases.
No details about inclusion/exclusion of G6PD-deficient/pregnant/breastfeeding patients.
Solari-Soto 2002 PER 
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Diagnosis: microscopy
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day for 7 days.
Directly observed therapy.
Primaquine given after chloroquine course.
Outcomes • Relapse.• Adverse events.
Follow-up: 60 days (total enrolment 60 days)
Notes Location: Peru
Setting: patients treated at San Martín de Pangoa Hospital, Junín
Funding: US Naval Medical Research Institute Detachment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details on allocation process.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Samples double-checked, but no details as to whether blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data accounted for, similar in each group.
Selective reporting (re-
porting bias)
Unclear risk No details.
Other bias Low risk We did not detect any other sources of bias.
Solari-Soto 2002 PER  (Continued)
Abbreviations: ACT: artemisinin-based combination therapy; CQ: chloroquine; CYP2D6: cytochrome P450 2D6; G6PD: glucose-6-phosphate
dehydrogenase; PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PQ:
primaquine; RCT: randomized controlled trial; SE: standard error; SR: sustained release; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adak 2001 No PQ comparison group.
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Study Reason for exclusion
Alvarez 2006 Comparison regimens are of a lower total dose than the control (15 mg/day for 3 days or 7 days) –
shown to be inferior in Galappaththy 2013.
Alvarez Sanchez 2007 Low-dose, shorter regimens of PQ.
Betuela 2012 Only one treatment group received primaquine.
Chu 2017 Wrong outcomes: primary outcome of this analysis was the fractional haematocrit reduction up to
day 14 after enrolment.
Chu 2018 No primaquine comparison arm.
Clyde 1977 Not an RCT, observational single-arm trial.
Contacos 1974 Not an RCT.
da Silva 1984 Not properly randomized (randomized according to whether the end of the notes code is odd or
even), low-dose comparison PQ group.
Gogtay 1999 Low-dose 15 mg for shorter time period (5 days) – shown to be ineffective in Galappaththy 2013.
Goller 2007 Not an RCT – logistic regression using already-published RCTs and observational studies (not pri-
mary trial).
Kim 2012 Wrong comparator: low-dose for 5 days - shown to be ineffective in Galappaththy 2013.
Kimura 1996 Not an RCT.
Krudsood 2008 Artesunate only as blood-stage treatment (does not meet inclusion criteria) and follow-up only 28
days.
Leslie 2004 No PQ comparison group: supervised versus unsupervised therapy.
Leslie 2008b Duplicate of Leslie 2008 PAK; conference abstract title only for session at ASTMH 57th Annual Meet-
ing.
Maneeboonyang 2011 Not randomized, participants were sequentially allocated into either the directly observed thera-
py (DOT) group or the self-administered therapy (SAT) group. No PQ comparison group, supervised
versus non-supervised therapy.
Miller 1974 Not an RCT.
Pasaribu 2013 No PQ comparison group.
Pukrittayakamee 2000 No PQ comparison group.
Sabchareon 1981 No blood-stage antimalarial treatment used in primaquine comparison group according to inclu-
sion criteria.
Saint-Yves IF 1977 Presumptive treatment of 45 mg PQ given to all participants before randomization.
Takeuchi 2010 No PQ comparison group: supervised versus non-supervised therapy.
Villalobos-Salcedo 2000 Wrong comparator: lower dose of PQ in comparison group (total dose 150 mg) - shown to be inef-
fective in Galappaththy 2013.
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Study Reason for exclusion
Warrasak 2018 No primaquine comparison arm, ophthalmological outcomes.
Abbreviations: PQ: primaquine; RCT: randomized controlled trial.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Improving the radical cure of vivax malaria: a multicentre randomised comparison of short and
long course primaquine regimens
Methods RCT, multicentre
Participant, care provider, and investigator blinding
Participants Aged 6 months and older.
Inclusion criteria:
• Participant (or parent/guardian of children below age of consent) is willing and able to give written
informed consent to participate in the trial; verbal consent in the presence of a literate witness
is required for illiterate patients. In addition, written assent (or verbal assent in the presence of a
literate witness for illiterates) from children 12 to 17 years as per local practice.• Monoinfection with P vivax of any parasitaemia in countries that use chloroquine as blood sch-
izonticidal therapy. Mixed infections with P vivax and P falciparum can be enrolled in countries
that use an artemisinin combination therapy.• Diagnosis based on rapid diagnostic tests.• Over 6 months of age.• Weight 5 kg or greater.• Fever (axillary temperature 37.5°C) or history of fever in the last 48 hours.• Able (in the investigator's opinion) and willing to comply with the study requirements and fol-
low-up.
Exclusion criteria:
• Female participant who is pregnant, lactating, or planning pregnancy during the course of the
study.• Inability to tolerate oral treatment.• Previous episode of haemolysis or severe haemoglobinuria following primaquine.• Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral
treatment - haemoglobin concentration less than 9 g/dL.• Known hypersensitivity or allergy to the study drugs.• Blood transfusion in last 90 days, since this can mask G6PD-deficient status.• A febrile condition due to diseases other than malaria (for example, measles, acute lower respira-
tory tract infection, severe diarrhoea with dehydration).• Presence of any condition which in the judgement of the investigator would place the participant
at undue risk or interfere with the results of the study (for example, serious underlying cardiac,
renal, or hepatic disease; severe malnutrition; HIV/AIDS; or severe febrile condition other than
malaria); co-administration of other medication known to cause haemolysis or that could inter-
fere with the assessment of antimalarial regimens.• Currently taking medication known to interfere significantly with the pharmacokinetics of pri-
maquine and the schizonticidal study drugs.• Prior antimalarial medications in the previous 7 days.
Locations: Afghanistan, Ethiopia, Indonesia, Vietnam
NCT01814683 
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Estimated enrolment: 3150 participants
Interventions 1. Standard blood schizonticidal therapy plus 7 days of supervised primaquine (7 mg/kg total dose)
administered once per day (1.0 mg/kg once daily) followed by 7 days of placebo
2. Standard blood schizonticidal therapy plus 14 days of supervised primaquine (7 mg/kg total
dose) administered once per day (0.5 mg/kg)
(3. Standard blood schizonticidal therapy plus 14 days placebo)
Outcomes • Incidence rate (per person-year) and risk of symptomatic recurrent P vivax [Time Frame: 12
months]. The incidence rate (that is, per person-year) of symptomatic recurrent P vivax para-
sitaemia (detected by microscopy) over 12 months of follow-up in the 7- versus 14-day primaquine
groups for all sites combined and stratified by site• Incidence rate (per person-year) of recurrent P vivax parasitaemia; haematological recovery; seri-
ous adverse drug reaction, primaquine tolerability, risk of severe anaemia in G6PD-deficient arm,
cost-effective analysis with respect to the use of G6PD tests
Starting date July 2014
Contact information Ric Price, University of Oxford; ric.price@ndm.ox.ac.uk
Notes Esimated completion date: December 2019
Protocol published (see IMPROV Study Group 2015; listed under NCT01814683)
clinicaltrials.gov/ct2/show/NCT01814683
NCT01814683  (Continued)
 
 
Trial name or title Evaluation of safety and efficacy of two primaquine dosing regimens for the radical treatment of
Plasmodium vivax malaria in Vanuatu and Solomon Islands
Methods RCT, open-label
Participants Children and adults aged 12 months to 60 years. Solomon Islands and Vanuatu.
Inclusion criteria:
• Age 12 months to 60 years.• Melanesian background and living in local area.• Microscopically (based on field microscopy) or RDT-confirmed P vivax regardless of parasite den-
sity. Mixed infections (P falciparum-P vivax and P malariae-P vivax) can be included.
Exclusion criteria:
• Any signs of severe malaria (see WHO definitions) including: impaired consciousness, respirato-
ry distress, severe anaemia (haemoglobin < 5), multiple seizures, frequent vomiting/inability to
swallow tablets, prostration, jaundice, hypotension, abnormal bleeding, or hypoglycaemia.• Clinical evidence of non-malarial illness (such as pneumonia or otitis media).• Severe malnutrition (weight-for-age nutritional Z score < 60th percentile).• Permanent disability that prevents or impedes study participation.• Treatment with primaquine in the previous 14 days.• Residence or planned travel outside the study area during the follow-up period (precluding su-
pervised treatment and follow-up procedures).• Known or suspected pregnancy.• Currently breastfeeding.
NCT01837992 
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• A positive rapid test for G6PD deficiency (Binax or Carestart RDT).
Interventions 1. Primaquine dose of 0.5 mg/kg/day for 14 consecutive days and standard age-based dosage 3-
day course of artemether-lumefantrine
2. Primaquine dose of 0.25 mg/kg for 14 consecutive days and standard age-based dosage 3-day
course of artemether-lumefantrine
(3. Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the
standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent
parasitaemia or completion of 3 months follow-up)
Outcomes • Efficacy: numbers of P vivax relapses per person-years of follow-up [Time Frame: 12 months].
Total number of microscopically diagnosed (including both symptomatic and asymptomatic in-
fections), PCR-confirmed relapses with P vivax in participants in each treatment arm over the 3-
month follow-up period, expressed as number of relapses per person-years of follow-up.• Safety and toxicity: mild, moderate, and severe adverse events, haemolysis, methaemoglobi-
naemia.
Starting date May 2013
Contact information Dr Ivo Mueller; mueller@wehi.edu.au
Notes Estimated completion date May 2015. Contacted for results - no response.
Protocol available at clinicaltrials.gov/ct2/show/NCT01837992
NCT01837992  (Continued)
Abbreviations: G6PD: glucose-6-phosphate dehydrogenase; RCT: randomized controlled trial; RDT: rapid diagnostic test; WHO: World
Health Organization.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   High-standard 14-day regimen versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence at 6 months' follow-up 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 6 months (chloroquine blood-
stage treatment)
1 639 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.47, 1.43]
1.2 6 months (chloroquine or ACT
blood-stage treatment)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.17, 7.09]
2 Recurrence (PCR-adjusted) 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 6 to 7 months 1 639 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.62, 5.40]
3 Serious adverse effects 1 778 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events that result in dis-
continuation of treatment
1 778 Risk Ratio (M-H, Fixed, 95% CI) 4.19 [0.90, 19.60]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5 Adverse effects known to occur
with primaquine
1 778 Risk Ratio (M-H, Fixed, 95% CI) 2.72 [0.98, 7.57]
6 Adverse events known to occur
with chloroquine
1 778 Risk Ratio (M-H, Fixed, 95% CI) 9.43 [0.51, 174.47]
 
 
Analysis 1.1.   Comparison 1 High-standard 14-day regimen versus
standard 14-day regimen, Outcome 1 Recurrence at 6 months' follow-up.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 6 months (chloroquine blood-stage treatment)  
Rajgor 2014 IND 21/317 26/322 100% 0.82[0.47,1.43]
Subtotal (95% CI) 317 322 100% 0.82[0.47,1.43]
Total events: 21 (0.5mg/kg/day PQ 14 days), 26 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.48)  
   
1.1.2 6 months (chloroquine or ACT blood-stage treatment)  
Saravu 2018 IND 2/18 2/20 100% 1.11[0.17,7.09]
Subtotal (95% CI) 18 20 100% 1.11[0.17,7.09]
Total events: 2 (0.5mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.11(P=0.91)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.76), I2=0%  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 1.2.   Comparison 1 High-standard 14-day regimen versus
standard 14-day regimen, Outcome 2 Recurrence (PCR-adjusted).
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 6 to 7 months  
Rajgor 2014 IND 9/317 5/322 100% 1.83[0.62,5.4]
Subtotal (95% CI) 317 322 100% 1.83[0.62,5.4]
Total events: 9 (0.5mg/kg/day PQ 14 days), 5 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.09(P=0.27)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Analysis 1.3.   Comparison 1 High-standard 14-day regimen versus
standard 14-day regimen, Outcome 3 Serious adverse eBects.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 0/380 0/398   Not estimable
   
Total (95% CI) 380 398 Not estimable
Total events: 0 (0.5mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 1.4.   Comparison 1 High-standard 14-day regimen versus standard 14-
day regimen, Outcome 4 Adverse events that result in discontinuation of treatment.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 8/380 2/398 100% 4.19[0.9,19.6]
   
Total (95% CI) 380 398 100% 4.19[0.9,19.6]
Total events: 8 (0.5mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 1.5.   Comparison 1 High-standard 14-day regimen versus standard 14-
day regimen, Outcome 5 Adverse eBects known to occur with primaquine.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 13/380 5/398 100% 2.72[0.98,7.57]
   
Total (95% CI) 380 398 100% 2.72[0.98,7.57]
Total events: 13 (0.5mg/kg/day PQ 14 days), 5 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.92(P=0.05)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Analysis 1.6.   Comparison 1 High-standard 14-day regimen versus standard 14-
day regimen, Outcome 6 Adverse events known to occur with chloroquine.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 4/380 0/398 100% 9.43[0.51,174.47]
   
Total (95% CI) 380 398 100% 9.43[0.51,174.47]
Total events: 4 (0.5mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 2.   0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence by 6 to 7 months' fol-
low-up
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
2 Recurrence by 6 to 7 months' fol-
low-up (PCR-adjusted)
2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Recurrence by 6 to 7 months sub-
grouped by geographical region
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
3.1 South America 2 397 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.26]
3.2 Asia 2 814 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.73, 1.94]
4 Recurrence by 6 to 7 months sub-
grouped by directly observed thera-
py (DOT) versus non-DOT
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
4.1 DOT 3 1017 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.67, 1.43]
4.2 Non-DOT 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.04, 5.20]
5 Serious adverse effects 5 1427 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events that result in dis-
continuation of treatment
5 1427 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.15, 7.38]
7 Adverse effects known to occur
with primaquine
4 1154 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.64, 1.76]
8 Anaemia or change in haemoglo-
bin status
1 240 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.91]
9 Adverse events known to occur
with chloroquine
1 779 Risk Ratio (M-H, Fixed, 95% CI) 9.40 [0.51, 174.01]
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Analysis 2.1.   Comparison 2 0.5 mg/kg/day for 7 days versus standard
14-day regimen, Outcome 1 Recurrence by 6 to 7 months' follow-up.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 0/39 2/40 4.83% 0.21[0.01,4.14]
Durand 2014 PER 16/156 22/162 42.25% 0.76[0.41,1.38]
Pareek 2015 IND 1/99 2/95 4% 0.48[0.04,5.2]
Rajgor 2014 IND 30/298 26/322 48.92% 1.25[0.76,2.06]
   
Total (95% CI) 592 619 100% 0.96[0.66,1.39]
Total events: 47 (0.5mg/kg/day PQ 7 days), 52 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=2.99, df=3(P=0.39); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.2.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day
regimen, Outcome 2 Recurrence by 6 to 7 months' follow-up (PCR-adjusted).
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Durand 2014 PER 8/156 12/162 0% 0.69[0.29,1.65]
Rajgor 2014 IND 12/298 5/322 0% 2.59[0.92,7.27]
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.3.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day
regimen, Outcome 3 Recurrence by 6 to 7 months subgrouped by geographical region.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.3.1 South America  
Abdon 2001 BRA 0/39 2/40 4.83% 0.21[0.01,4.14]
Durand 2014 PER 16/156 22/162 42.25% 0.76[0.41,1.38]
Subtotal (95% CI) 195 202 47.08% 0.7[0.39,1.26]
Total events: 16 (0.5mg/kg/day PQ 7 days), 24 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%  
Test for overall effect: Z=1.19(P=0.23)  
   
2.3.2 Asia  
Pareek 2015 IND 1/99 2/95 4% 0.48[0.04,5.2]
Rajgor 2014 IND 30/298 26/322 48.92% 1.25[0.76,2.06]
Subtotal (95% CI) 397 417 52.92% 1.19[0.73,1.94]
Total events: 31 (0.5mg/kg/day PQ 7 days), 28 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=0.59, df=1(P=0.44); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
Favours 0.5mg/kg/day PQ 1000.01 100.1 1 Favours 0.25mg/kg/day PQ
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Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 592 619 100% 0.96[0.66,1.39]
Total events: 47 (0.5mg/kg/day PQ 7 days), 52 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=2.99, df=3(P=0.39); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
Test for subgroup differences: Chi2=1.86, df=1 (P=0.17), I2=46.1%  
Favours 0.5mg/kg/day PQ 1000.01 100.1 1 Favours 0.25mg/kg/day PQ
 
 
Analysis 2.4.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome
4 Recurrence by 6 to 7 months subgrouped by directly observed therapy (DOT) versus non-DOT.
Study or subgroup 0.5 mg/kg/
day PQ 7 days
0.25 mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.4.1 DOT  
Abdon 2001 BRA 0/39 2/40 4.83% 0.21[0.01,4.14]
Durand 2014 PER 16/156 22/162 42.25% 0.76[0.41,1.38]
Rajgor 2014 IND 30/298 26/322 48.92% 1.25[0.76,2.06]
Subtotal (95% CI) 493 524 96% 0.98[0.67,1.43]
Total events: 46 (0.5 mg/kg/day PQ 7 days), 50 (0.25 mg/kg/day PQ 14
days)
 
Heterogeneity: Tau2=0; Chi2=2.64, df=2(P=0.27); I2=24.28%  
Test for overall effect: Z=0.12(P=0.91)  
   
2.4.2 Non-DOT  
Pareek 2015 IND 1/99 2/95 4% 0.48[0.04,5.2]
Subtotal (95% CI) 99 95 4% 0.48[0.04,5.2]
Total events: 1 (0.5 mg/kg/day PQ 7 days), 2 (0.25 mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
   
Total (95% CI) 592 619 100% 0.96[0.66,1.39]
Total events: 47 (0.5 mg/kg/day PQ 7 days), 52 (0.25 mg/kg/day PQ 14
days)
 
Heterogeneity: Tau2=0; Chi2=2.99, df=3(P=0.39); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
Test for subgroup differences: Chi2=0.33, df=1 (P=0.56), I2=0%  
Favours 0.5mg/kg/day PQ 1000.01 100.1 1 Favours 0.25mg/kg/day PQ
 
 
Analysis 2.5.   Comparison 2 0.5 mg/kg/day for 7 days versus
standard 14-day regimen, Outcome 5 Serious adverse eBects.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 0/40 0/40   Not estimable
Durand 2014 PER 0/156 0/162   Not estimable
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Pareek 2015 IND 0/99 0/95   Not estimable
Rajgor 2014 IND 0/381 0/398   Not estimable
Solari-Soto 2002 PER 0/28 0/28   Not estimable
   
Total (95% CI) 704 723 Not estimable
Total events: 0 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.6.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day
regimen, Outcome 6 Adverse events that result in discontinuation of treatment.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 0/40 0/40   Not estimable
Durand 2014 PER 0/156 0/162   Not estimable
Pareek 2015 IND 0/99 0/95   Not estimable
Rajgor 2014 IND 2/381 2/398 100% 1.04[0.15,7.38]
Solari-Soto 2002 PER 0/28 0/28   Not estimable
   
Total (95% CI) 704 723 100% 1.04[0.15,7.38]
Total events: 2 (0.5mg/kg/day PQ 7 days), 2 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.7.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-
day regimen, Outcome 7 Adverse eBects known to occur with primaquine.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 6/39 11/40 42.18% 0.56[0.23,1.36]
Pareek 2015 IND 11/120 10/120 38.83% 1.1[0.49,2.49]
Rajgor 2014 IND 10/381 5/398 18.99% 2.09[0.72,6.06]
Solari-Soto 2002 PER 0/28 0/28   Not estimable
   
Total (95% CI) 568 586 100% 1.06[0.64,1.76]
Total events: 27 (0.5mg/kg/day PQ 7 days), 26 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=3.54, df=2(P=0.17); I2=43.55%  
Test for overall effect: Z=0.22(P=0.82)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Analysis 2.8.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-
day regimen, Outcome 8 Anaemia or change in haemoglobin status.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Pareek 2015 IND 1/120 0/120 100% 3[0.12,72.91]
   
Total (95% CI) 120 120 100% 3[0.12,72.91]
Total events: 1 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.9.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-
day regimen, Outcome 9 Adverse events known to occur with chloroquine.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 4/381 0/398 100% 9.4[0.51,174.01]
   
Total (95% CI) 381 398 100% 9.4[0.51,174.01]
Total events: 4 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 3.   0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 5 months 1 129 Risk Ratio (M-H, Fixed, 95% CI) 5.23 [0.28, 99.15]
1.2 8 months 1 126 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.38, 127.32]
1.3 11 months 1 122 Risk Ratio (M-H, Fixed, 95% CI) 3.18 [0.37, 27.60]
2 Serious adverse effects 1 129 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Anaemia (haemoglobin < 7 g/
dL)
1 129 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 3.1.   Comparison 3 0.75 mg/kg primaquine/week for 8
weeks versus high-standard 14-day regimen, Outcome 1 Recurrence.
Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.1.1 5 months  
Leslie 2008 PAK 3/74 0/55 100% 5.23[0.28,99.15]
Subtotal (95% CI) 74 55 100% 5.23[0.28,99.15]
Total events: 3 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
   
3.1.2 8 months  
Leslie 2008 PAK 4/71 0/55 100% 7[0.38,127.32]
Subtotal (95% CI) 71 55 100% 7[0.38,127.32]
Total events: 4 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
   
3.1.3 11 months  
Leslie 2008 PAK 4/68 1/54 100% 3.18[0.37,27.6]
Subtotal (95% CI) 68 54 100% 3.18[0.37,27.6]
Total events: 4 (0.75mg/kg PQ weekly 8wks), 1 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
Test for subgroup differences: Chi2=0.2, df=1 (P=0.91), I2=0%  
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
 
 
Analysis 3.2.   Comparison 3 0.75 mg/kg primaquine/week for 8 weeks
versus high-standard 14-day regimen, Outcome 2 Serious adverse eBects.
Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Leslie 2008 PAK 0/74 0/55   Not estimable
   
Total (95% CI) 74 55 Not estimable
Total events: 0 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
 
 
Analysis 3.3.   Comparison 3 0.75 mg/kg primaquine/week for 8 weeks versus
high-standard 14-day regimen, Outcome 3 Anaemia (haemoglobin < 7 g/dL).
Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Leslie 2008 PAK 0/74 0/55   Not estimable
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
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Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 74 55 Not estimable
Total events: 0 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
 
 
Comparison 4.   0.375 mg/kg/day primaquine for 14 days versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 6 months' follow-up 1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.01, 3.34]
1.2 12 months' follow-up 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 18 months' follow-up 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 4.1.   Comparison 4 0.375 mg/kg/day primaquine for 14
days versus standard 14-day regimen, Outcome 1 Recurrence.
Study or subgroup 0.375mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.1.1 6 months' follow-up  
Bunnag 1994 THA 0/40 2/33 100% 0.17[0.01,3.34]
Subtotal (95% CI) 40 33 100% 0.17[0.01,3.34]
Total events: 0 (0.375mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.17(P=0.24)  
   
4.1.2 12 months' follow-up  
Bunnag 1994 THA 0/24 0/25   Not estimable
Subtotal (95% CI) 24 25 Not estimable
Total events: 0 (0.375mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.1.3 18 months' follow-up  
Bunnag 1994 THA 0/19 0/19   Not estimable
Subtotal (95% CI) 19 19 Not estimable
Total events: 0 (0.375mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14
days)
 
Favours 0.375mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Study or subgroup 0.375mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours 0.375mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 5.   1.17 mg/kg/day primaquine for 3 days versus standard 14-day regimen; follow-up 4 months
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Recurrence 1 129 Risk Ratio (M-H, Fixed, 95% CI) 3.88 [2.11, 7.11]
 
 
Analysis 5.1.   Comparison 5 1.17 mg/kg/day primaquine for 3 days versus
standard 14-day regimen; follow-up 4 months, Outcome 1 Recurrence.
Study or subgroup 1.17mg/kg/
day PQ 3 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Carmona-Fonseca 2009 COL 37/63 10/66 100% 3.88[2.11,7.11]
   
Total (95% CI) 63 66 100% 3.88[2.11,7.11]
Total events: 37 (1.17mg/kg/day PQ 3 days), 10 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=4.37(P<0.0001)  
Favours 1.17mg/kg/day PQ 3 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
A D D I T I O N A L   T A B L E S
 
Objective Intervention Control
Are higher doses (0.5
mg/kg/day or 30 mg/
day primaquine for 14
days) more effective in
all areas, or only in areas
where they are standard
treatment (East Asia and
Oceania)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg/day (adult dose 30
mg) for 14 days (total dose 420 mg).
Both intervention and control groups
must have received the same treatment
for the blood-borne stage of infection,
that is, either CQ or ACT.
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg).
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Are shorter, higher-dose
regimens of primaquine
over 7 days as effective
as treatment over 14
days (is the total dose
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg/day (adult dose 30
mg) for 7 days (total dose 210 mg) or 1
mg/kg/day (adult dose 60 mg) for 7 days
(total dose 420 mg).
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg) or high-standard 14-day course primaquine (0.5 mg/
kg/day, adult dose 30 mg, total dose 420 mg).
Table 1.   Data extraction: grouping of comparisons to address the review's objectives 
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rather than the length of
treatment the important
factor)?
Both intervention and control groups
must have received the same treatment
for the blood-borne stage of infection,
that is, either CQ or ACT.
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Are weekly dosing regi-
mens (0.75 mg/kg/week
or 45 mg/week for 8
weeks) as effective?
Blood-stage antimalarial drug with pri-
maquine 0.75/kg (45 mg) per week for 8
weeks (total dose 360 mg)
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg) or high-standard 14-day course primaquine (0.5 mg/
kg/day, adult dose 30 mg, total dose 420 mg).
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Table 1.   Data extraction: grouping of comparisons to address the review's objectives  (Continued)
Abbreviations: ACT = artemisinin-based combination therapy; CQ = chloroquine.
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
 
PubMed MEDLINE
1 primaquine [Title/Abstract]
2 "Primaquine"[Mesh]
3 1 or 2
4 "plasmodium vivax" [Title/Abstract]
5 "Plasmodium vivax"[Mesh]
6 "vivax malaria " [Title/Abstract]
7 "Malaria, Vivax"[Mesh]
8 4 or 5 or 6
9 3 and 8
10 "Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publication Type]
11 randomized or placebo [Title/Abstract]
12 randomly or trial or groups [Title/Abstract]
13 "drug therapy" [Subheading]
14 10 or 11 or 12 or 13
15 9 and 14
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Cochrane Library
Issue 12 2018
ID Search
#1 primaquine: ti,ab,kw: (Word variations have been searched)
#2 MeSH descriptor: [Primaquine] explode all trees
#3 #1 or #2
#4 "plasmodium vivax": ti, ab,kw (Word variations have been searched)
#5 MeSH descriptor : [Malaria, Vivax] explode all trees
#6 MeSH descriptor: [Plasmodium vivax ] explode all trees
#7 #4 or #5 or #6
#8 #3 and #7
Embase
1947-Present, updated daily
--------------------------------------------------------------------------------
1 "primaquine".mp.
2 primaquine/
3 1 or 2
4 plasmodium vivax.mp. or Plasmodium vivax/
5 malaria vivax.mp. or Plasmodium vivax malaria/
6 4 or 5 or 6
7 controlled clinical trial.mp. or Controlled Clinical Trial/
8 randomized controlled trial.mp. or Randomized Controlled Trial/
9 (randomized or placebo or double-blind* or single-blind*).mp.
10 randomization/
11 crossover procedure/
12 7 or 8 or 9 or 10 or 11
13 3 and 6 and 12
LILACS
Search on : primaquine [Words] and malaria vivax or plasmodium vivax [Words]
ClinicalTrials.gov and WHO ICTRP
primaquine and vivax
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We changed the inclusion criteria for trials to add 30 mg (0.5 mg/kg/day) for 14 days, as this is a World Health Organization-recommended
regimen, and some trials use it as the control group for this reason.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antimalarials  [administration & dosage]  [*therapeutic use];  Drug Administration Schedule;  Malaria, Vivax  [*drug therapy];  Primaquine
 [administration & dosage]  [*therapeutic use];  Primary Prevention;  Randomized Controlled Trials as Topic;  Recurrence
MeSH check words
Humans
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
57
